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The Adenosinergic system 
The nucleoside adenosine (Figure 1) is formed by a molecule of the purinergic nucleobase 
adenine bound to a ribose. Adenosine is a neuromodulator/neurotransmitter in the CNS, usually 
with a cytoprotective function (Fredholm et al., 2007).  
This nucleoside is central in the regulation of several physiological functions in different cell 
type (neurons, platelets, mast cells, smooth muscle cells, myocytes), due to its role as modulator 
of neurotransmission, conduction, vasodilation, proliferation and cell death. 
 
Figure 1. Adenosine molecular structure. 
 
Many of the actions mediated by adenosine, are responsible of tissue protection during 
situations of stress, such as ischemia or hypoxia. Protective effects and tissue repair are exerted 
by adenosine by increasing the supply of oxygen, by triggering anti-inflammatory responses 
and by promoting angiogenic processes (Linden, 2005). 
In the Nervous System, adenosine acts both at central and peripheral level. In 1929, Drury and 
Szent-Györgyi, proved that systemic administration of adenosine in anesthetized animals 
induced transient bradycardia, vasodilation, decrease of blood pressure and intestinal motility. 
In the years 1970s Sattin and Rall (Sattin et al., 1970) showed a specific role of adenosine in 
the central nervous system (CNS), in the increase of cAMP formation in mammalian brain 
slices. This effect was inhibited by the methylxanthines: caffeine and theophylline. 
Later on, a depressant role of adenosine on the firing of cortical (Phillis et al., 1979) and 
cerebellar neurons (Kostopoulos et al., 1975) and on excitatory synaptic potential amplitude in 
cortical and hippocampal slices (Kuroda et al., 1976; Dunwiddie et al., 1980; Okasa et al., 1980) 
was demonstrated. Moreover, it was shown the inhibitory role of adenosine on the acetylcholine 
release in different brain areas (Harms et al., 1978) and on the release of dopamine (Michaelis 
et al., 1979), noradrenaline (Harms et al., 1978), excitatory amino acids (Corradetti et al., 1984) 
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and serotonin (Harms et al., 1979). All these effects were inhibited by methylxanthines, 
increased by inhibitors of the adenosine reuptake and correlated with changes in cAMP levels.  
 
1.1 Adenosine formation 
 In the CNS, adenosine originates from neurons and from non-neuronal cells such as glial cells 
(Halassa et al., 2009). Its formation occurs by dephosphorylation of AMP operated by 5'-
nucleotidases. These enzymes are present both intracellularly, (5'-endonucleotidase), and 
extracellularly, (5'-ectonucleotidase) (Zimmermann, 1992 a). Intracellularly adenosine is 
generated from AMP and extracellularly by enzymatic conversion of released nucleotides 
through coupled ectonucleotidases: CD39 that converts ATP/ADP to AMP and CD73 that 
hydrolyses AMP to adenosine. A further enzyme able to generate adenosine by sequential 
hydrolysis of ATP, is the alkaline phosphatase (Zimmermann, 2000).  
The intracellular adenosine was considered as the most important source of extracellular 
adenosine. Over the past decade however, it was increasingly recognized that the rapid (1 ms) 
extracellular conversion of locally released ATP by ectonucleotidases represents another 
important source of extracellular adenosine in tissue (Fredholm et al., 2007).  
Another possible source of extracellular adenosine is represented by released cAMP. In the 
extracellular space, cAMP can be converted to 5'-AMP by ecto-phosphodiesterase, and then to 
adenosine by 5'-ectonucleotidase. Alternatively, cAMP can be converted into 5'-AMP within 
the cell and then released in the extracellular space, where it represents a further source of 
adenosine. This suggests that many neurotransmitters that act on metabotropic receptors whose 
signaling is linked to adenylate cyclase, by favouring the accumulation of cAMP, may regulate 
the adenosine levels and thus the inhibitory effects in the CNS (Latini et al., 2001 a). 
Adenosine can also derive from S-adenosylhomocysteine (SAH) hydrolysis by the enzyme 
SAH-hydrolase (Figure 2). This reaction occurs mainly at cardiac level, where SAH represents 
an important source of intracellular adenosine but only in physiological and not under hypoxic 
conditions (Latini et al., 1996 a). At neuronal level, this synthesis pathway does not significantly 
contribute to the adenosine production either in normoxic or in hypoxic conditions (Pak et al., 
1994; Latini et al., 1996 b). 
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1.1.1 5’Endonucleotidases  
Six 5'-endonucleotidases with different subcellular localization have been cloned in mammals 
(Table 1): 
 
5’-Nucleotidase 
(abbreviation)  
 Aliases Natural substrates 
cytosolic 5’-nucleotidase I (cN-I) cN-IA AMP-specific;  AMP, dTMP, dCMP,  
dGMP, dAMP, dIMP,  
(probable substrate = dUMP) 
cN-IB cN-IA homologue;  
AIRP 
AMP 
cytosolic 5’-nucleotidase II (cN-II)  high Km 5'-NT;  
purine 5'-NT;  
GMP, IMP-specific 
5'-NT 
Nucleotidase reaction: IMP,  
dIMP, GMP, dGMP, XMP.  
Phosphotransfer reaction:  
inosine and Deoxyinosine 
cytosolic 5’-nucleotidase III (cN-III)  PN-I;  
P5'N-1;  
UMPH 
Nucleotidase reaction: CMP,  
UMP, dUMP, dCMP, dTMP.  
Phosphotransfer reaction:  
Uridine, Cytidine,  
Deoxycytidine 
cytosolic 5’(3')-nucleotidase (cdN)  dNT-1;  
PN-II 
3’-dUMP, 3’-dTMP,  
3’-UMP, 2’-UMP,  
5’-dIMP, 5’-dUMP, 
5’-dCMP,5’-dTMP,  
5’-dAMP 
mitochondrial 5'(3')-nucleotidase 
(mdN) 
 dNT-2 5’-dUMP, 5’-dTMP, 
3’-dTMP, 5’-, 3’-, 2’-dUMP 
Table 1. Classification of 5’-endonucleotidases. Modified from (Bianchi et al., 2003). 
 
Three different cytosolic 5'-nucleotidases cN-I, cN-II, and cN-III have been described; among 
them, the AMP-selective 5’-nucleotidase (cN-I) mostly accounts for adenosine during enhanced 
oxygen demand or metabolic load. Two different isoforms of cN-I enzyme exist: cN-IA and 
cN-IB. cN-IA is able to hydrolyse several substrates but has a preference for AMP. It has been 
purified from a variety of different tissues including the brain. cN-IB is less characterized and 
has the lowest expression in the brain (Sala-Newby et al., 2001).  
Adenosine can be formed intracellularly from AMP not under basal physiological normoxic 
conditions but only under different stress conditions (i.e. depolarization, ischemia/hypoxia, 
seizures) when AMP concentrations increases because of ATP breakdown (Sala-Newby et al., 
2000). Only in these conditions, AMP concentration reaches a value in the range of cN-I 
affinity. In fact the Km of cN-I for AMP (1.2–8.3 mM) is higher than the intracellular 
concentrations of AMP that have been evaluated under physiological conditions (in rat brain 
30–40 µM) (Traut, 1994). Therefore, a massive production of adenosine can occur only in 
response to a condition of energy imbalance when ATP consumption exceeds the capacity of 
its own re-synthesis, with a consequent production of adenosine (Dunwiddie et al., 1997). 
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Typically, in pathological conditions such as ischemia when the energy imbalance is massive, 
the resulting massive AMP production is the key mechanism that accounts for adenosine 
formation (Melani et al., 2006 a). In this condition, adenosine cannot be efficiently re-
phosphorylated to ATP due to the lack of oxygen and glucose.  
In addition, since ATP and ADP inhibit the 5’-endonucleotidase activity, a reduction in the 
intracellular concentration of ATP and ADP leads to the enzyme activation (Meghji, 1993). 
 
1.1.2 5’Ectonucleotidases 
Ecto-5'-nucleotidase (CD73 or 5’-NT) is the enzyme that catalyses the terminal 
dephosphorylation of 5'–AMP. 5'-ectonucleotidases allow the transformation of the nucleotides 
released outside the cell into adenosine. These enzymes are homodimers anchored to the plasma 
membrane through a molecule of glycosyl–phosphatidylinositol. Their catalytic site faces the 
extracellular space where 5’-ectonucleotidases exert their enzymatic action. CD73 hydrolyses 
several nucleosides 5'–monophosphate such as: CMP, UMP, GMP, IMP and AMP. On the basis 
of the Vmax/Km ratio, AMP is the most efficient (Naito et al., 1981) and physiological substrate 
(Zimmermann, 1992 a), with adenosine being the major nucleoside produced by CD73 
(Hunsucker et al., 2005). In fact, CD73 is the major enzyme responsible for the formation of 
extracellular adenosine from released adenine nucleotides (Zimmermann, 2000). 
CD73 is ubiquitously expressed both in central and peripheral nervous system. In CNS it is 
expressed poorly in proximity of neurons in comparison to glial cells: astrocytes,  
oligodendrocytes and microglia (Kreutzberg et al., 1978; Zimmermann, 1992 b; Schoen et al., 
1993; Resta et al., 1998; Spychala, 2000) . Pathological conditions such as ischemia and 
hypoxia are major inducers of CD73 expression (Kitakaze et al., 1996; Braun et al., 1997; 
Ledoux et al., 2003). Moreover, the modulation of the adenosine formation is central since it 
impacts on neurotransmission processes and CD73 has been reported as the major regulator of 
the adenosinergic signaling in the mouse brain (Kulesskaya et al., 2013). 
CD73 action is limited by ATP and ADP, that act as inhibitors with a Ki in the low micromolar 
range (Zimmermann, 1992 b). In fact, in striatal cholinergic synapses it has been shown that 
ATP, released in response to a high frequency stimulation, can be degraded to adenosine only 
at the end of the stimulation, when the concentrations of ATP and ADP decrease under the 
threshold of inhibition of the enzyme (James et al., 1993).  
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1.2 Adenosine release 
The mode of adenosine release may differ depending on experimental conditions. After 
electrical stimulation in vitro, adenosine seems to originate directly from cells, while in 
ischemic experimental models in vitro, adenosine might have also an extracellular origin due 
to the degradation of the adenosine nucleotides released following changes in membrane 
permeability (Pedata et al., 1993). 
Adenosine concentrations are regulated by a bidirectional flow mediated by transporters. These 
transporters are divided into two categories: those capable of a bidirectional transport across 
the plasma membrane of both purines and pyrimidines, according their concentration gradient 
(equilibrative transporters); and transporters that mediate the nucleotide influx thank to the 
coupling with sodium transporters (concentrative). Both transporters have been cloned and 
classified as: ENT1 and ENT2, equilibrative transporters; CNT1 and CNT2, concentrative 
transporters (Williams et al., 1991; Anderson et al., 1996; Baldwin et al., 1999). The 
equilibrative transporters work bidirectionally in order to maintain the intracellular and 
extracellular concentrations of adenosine in a range of 30-300 nM (Dunwiddie et al., 1997). 
Inhibitors of adenosine equilibrative transporters such as dypiridamole might increase or 
decrease the efflux of adenosine differently according to the physiopathological  conditions. 
Under in vivo physiological conditions dypiridamole increases adenosine efflux from the 
striatum indicating that the equilibrative carrier transports adenosine into cells (Pazzagli et al., 
1993;  Melani et al., 2012). Conversely, under conditions of energetic imbalance, dypiridamole 
decreases extracellular adenosine indicating that the equilibrative carrier transports adenosine 
out of the cells (Latini et al., 2001 a).  
It has been observed that tetrodotoxin (TTX) completely blocks adenosine release in brain slices 
electrically stimulated and that a reduction of extracellular Ca2+ concentration can cause a 
remarkable reduction of adenosine release (Pedata et al., 1990). Most recently it was 
demonstrated that adenosine efflux occurring in vivo from the striatum under normoxic 
physiological conditions does not arises from extracellular degradation of nucleotides and is 
not inhibited by dypiridamole (Melani et al., 2012 a). Under these conditions the efflux of 
adenosine is Ca2+sensitive (Melani et al., 2012 a) and is inhibited by TTX (Pazzagli et al., 1993; 
Dobolyi et al., 2000).  On the all observations in vitro and in vivo led to speculate that adenosine 
efflux under normoxic physiological conditions is consequent to electrical activity propagated 
along the typical modality of nervous cells that involves activity of voltage-gated Na+ channels. 
In fact, the TTX sensitivity and the Ca2+ dependency of adenosine release indicate that 
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adenosine release occurs by an excitation-secretion modality which is typical of 
neurotransmitters. Observation that the presence of adenosine is associated with intracellular 
vesicles support the notion that adenosine is stored in vesicles and released by exocytosis in an 
excitation-secretion modality typical of neurotransmitters (Corti et al., 2013). 
 
1.3 Adenosine catabolism 
Adenosine metabolism is regulated by two enzymes: adenosine deaminase (ADA) and 
adenosine kinase (AK) (Figure 2). ADA degrades adenosine to inosine having a Km in the 
range of 17–45 µM (Phillips et al., 1979) and it is present both at intracellular and at 
extracellular sites where is anchored to the plasma membrane (Franco et al., 1986).  
AK is an enzyme that converts adenosine to AMP, it is characterized by high specificity and a 
Km for adenosine of 2 µM (Phillips et al., 1979). 
Since the basal endogenous levels of adenosine are in the nanomolar range, it is likely that 
under physiological conditions the main degradation pathway is the phosphorylation operated 
by AK, while the action of extracellular ADA is important only when significant increases in 
adenosine concentration occur, such as during ischemia (Latini et al., 2001). 
 
 
Figure 2. Adenosine synthesis, catabolism and transport. Adenosine is produced intracellularly by AMP 
dephosphorylation or by SAH hydrolysis and then released from the cell through specific membrane 
transporters, or extracellularly by ATP hydrolysis. Adenosine is deaminated by ADA and converted to 
inosine. ADA, adenosine deaminase; AK, adenosine kinase; AOPCP, α, β-methylene ADP; DCF, 
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deoxyicoformicin; EHNA, erythro-9-(2-hydroxy-3-nonyl) adenosine; es, sensitive transporter ei,  
insensitive transporter; 5-IT, 5-iodotubercidin; NBMPR, nitrobenzylthioinosine; PDE, cAMP-
phosphodiesterase; SAH, S-adenosyl-homocysteine. From (Latini et al., 2001). 
 
1.4 Adenosine receptors 
Adenosine receptors were initially distinguished into two receptor classes: A1 and A2 on the 
basis of their excitatory or inhibitory actions on adenylyl cyclase (van Calker et al., 1979). 
Subsequently, molecular cloning and pharmacological studies have identified four subtypes of 
adenosine receptors: A1, A2A, A2B and A3 receptors (Fredholm et al., 2001).  
All adenosine receptors have been cloned from rat, mouse and human tissues (Fredholm et al., 
2001). Key features for their classification are their amino acid sequence, the coupled G-protein 
and the affinity for the endogenous ligand. 
All receptors are metabotropic heteromeric G-protein coupled receptor (GPCR). Typically, 
their structure is formed by a polypeptide chain characterized by 7 transmembrane hydrophobic 
domains with α helix structure (7TM, helices 1-7) of approximately 25 residues followed by 
one short membrane-associated helix (helix 8). TM domains are closely associated by three 
extra-cellular loops (ECL1-3) and three intracellular loops (ICL1-3) (Cristalli et al., 2008). 
Biochemical experiments and computational approaches have revealed the importance of the 
TM3 and TM7 in binding the endogenous ligand and agonist molecules (Rivkees et al., 1995). 
All adenosine receptors present an extra-cellular amino terminus (N-terminus) and a cytosolic 
carboxy terminus (C-terminus), (Cristalli et al., 2008) (Figure 3). The extracellular N-terminus 
contains one or more glycosylation sites, while the intracellular C-terminus provides sites for 
phosphorylation and palmitoylation, thereby playing a role in receptor desensitization and 
internalization mechanisms (Borea et al., 2018). Recently, details of the structures of human A1 
and A2A receptors have been provided by X-ray crystallography  (Jaakola et al., 2008; Lebon et 
al., 2011; Carpenter et al., 2016; Glukhova et al., 2017) and by electron cryo-microscopy (cryo-
EM) studies (Draper-joyce et al., 2018; García-Nafría et al., 2018), which are useful to obtain  
new GPCR structural information and   in the structure-based drug design of A1 and A2A  
receptors ligands (Glukhova et al., 2017; Sun et al., 2017).  
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Figure 3. Schematic representation of the molecular structure of the A2A receptor. From (Cristalli et al.,  
2008). 
 
A1, A2A, A2B amino acid sequence is well conserved among mammalian species, except for A 3 
receptors (Burnstock et al., 2011). This subtype is the latest cloned and pharmacologically 
characterized (Linden et al., 1993), and presents a considerable structural variability among 
different species. For instance, almost 30% difference in the amino acid sequence is found 
between humans and rat (Linden, 1994). 
Adenosine receptors transduce signals via G proteins. Hence, A1 and A3 subtypes are associated 
with Gi activation, adenylyl cyclase inhibition and decrease of intracellular cAMP levels, while 
A2A and A2B receptors are linked to Gs proteins that activate the same enzyme increasing cAMP 
concentration in the cytosol. However, adenosine receptors have also been reported to couple 
to other G-proteins, modulating different second messenger systems. For instance, in addition 
to their effects on adenylate cyclase (and contrary to adenosine A2A receptors) adenosine A1, 
A2B and A3 receptors are also characterized by their stimulatory effect on PLC (Abbracchio et 
al., 1995; Feoktistov et al., 1997) while A1 and A3 receptors can also activate PLD (Fredholm 
et al., 2001). 
In addition, by a direct G protein-channel interaction or by second messenger systems adenosine 
receptor stimulation also modulates several types of Ca2+ and K+ channels (Figure 4).  
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Figure 4. Adenosine receptors and signal transduction mechanisms. Adenosine receptors are G protein-
coupled receptors. The A1 and A3 subtypes inhibit adenylate cyclase via Gi protein, while the A2A and 
A2B receptors mediate stimulation of the enzyme via Gs protein. In addition, A1, A3 and A2B receptors 
can modulate, by Go protein or Gq, phospholipase activity, inducing the production of diacylglycero l 
(DAG) and inositol-triphosphate (IP3) and an increase in Ca2+ release from intracellular deposits. 
 
Another key feature for adenosine receptor subtypes classification is the affinity for their 
endogenous ligand. A1, A2A and A3 receptors have high affinity for the endogenous ligand, 
being activated by nanomolar concentrations of adenosine (Fredholm et al., 2011). On the 
contrary, the affinity values of A2B receptors for adenosine evaluated in binding and functional 
experiments are higher than 1 µM (Fredholm et al., 2011). Under physiological conditions, 
extracellular adenosine concentrations are estimated in the range of 30 to 200 nM (Latini et al., 
2001). These levels are sufficient to activate A1, A2A and A3 receptors subtypes, but not A2B, 
which require higher concentrations (micromolar range) of adenosine to be activated. Such 
higher adenosine concentrations are only reached under pathological conditions, such as during 
hypoxia or ischemia in vivo (Pedata et al., 2001) and in vitro (Latini et al., 1999). 
 
1.4.1 A1 Receptor: molecular structure, distribution and function 
The A1 receptor is a monomeric glycoprotein of 35-36 kDa formed by 326 amino acids. It is 
highly conserved with an 87%-92% homology between different species. It is coupled with the 
Gi/0 protein at the TM3 loop. The different effects of the stimulation of Gi/0 are mediated by 
both α subunit and βγ complex (Birnbaumer, 1992). A1 receptor mediates: inhibition of 
adenylate cyclase, activation of several types of K+ channels (probably via β,γ-subunits), 
inactivation of N, P and Q-type Ca2+ channels, stimulation of phospholipase C (PLC) 
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(Burnstock et al., 2011), and stimulation of phospholipase D (PLD) (Fredholm et al., 2001) 
(Figure 5). 
 
Figure 5. Overview of adenosine A1 receptor (A1AR) intracellular signaling pathways. A1AR 
stimulation decreases adenylate cyclase (AC) activity and cAMP production, thus inhibiting protein 
kinase A (PKA), while activated phospholipase C (PLC)-β, and Ca2+. K+ and Ca2+ channels are opened 
and closed, respectively, by A1AR enrollement. Mitogen-activated protein kinases p38, ERK1/2, and 
JNK1/2 phosphorylation are induced by A1AR activation. Modified from (Borea et al., 2018). 
 
The highest levels of A1 receptor expression are found in the CNS, suggesting a particularly 
important role of adenosine in brain functions. In rat the highest expression of A1 receptors has 
been found in the cortex, hippocampus, cerebellum and dorsal horn of the spinal cord; 
intermediate levels in basal ganglia structures including the striatum (Dixon et al., 1996). 
mRNA encoding A1 receptors is present in large striatal cholinergic interneurons (Dixon et al., 
1996) and in neurons of the globus pallidus, subthalamic nucleus and thalamus. An abundant 
expression of adenosine A1 receptor also occurs in the trigeminal ganglia, supporting a role of 
this receptor in pain regulation (Schindler et al., 2001). Neuronal A1 receptors are localized 
both pre- and post-synaptically (Deckert et al., 1988). In the hippocampus subcellular analysis 
of nerve terminals revealed that A1 receptor immunoreactivity is strategically located in the 
active zone of presynaptic terminals, as expected on the basis of the ability of A1 receptor 
agonists to depress neurotransmitter release. It has also been demonstrated that A1 receptor 
immunoreactivity is evident at postsynaptic sites together with NMDA receptor subunits NR1, 
NR2A and NR2B and with N-and P/Q-type Ca2+ channel immunoreactivity, emphasizing the 
importance of A1 receptors in the control of dendritic integration  A1 receptors can be found 
also extrasynaptically on dendrites (Rivkees et al., 1995) and on the axonal fibres of the 
hippocampus (Swanson et al., 1995). Activation of A1 receptors along the axon may be a 
powerful extra synaptic mechanism by which adenosine alters axonal electric transmission to 
inhibit neurotransmitter release (Swanson et al., 1995).  
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Under physiological conditions A1 receptors mediate sedative-hypnotic, anti-epileptic and anti-
nociceptive effects (Dunwiddie, 1985) by exerting a tonic inhibition of synaptic transmission 
both in vitro and in vivo. This has been demonstrated in several brain regions containing a high 
concentration of A1 receptors such as the hippocampus, but also in striatum and olfactory cortex 
(Von Lubitz, 1999; Latini et al., 2001). The inhibitory effect of adenosine A1 receptor 
stimulation has a pre- and post-synaptic component. At pre-synaptic level, the activation of A1 
receptor reduces Ca2+ influx through the preferential inhibition of N-type and, probably, Q-type 
channels (Yawo et al., 1993; Wu et al., 1994), with a consequent decrease in transmitters release 
(Prince et al., 1992). In fact, adenosine, by stimulation of A1 receptor, has been found to inhibit 
the release of all classic neurotransmitters: glutamate, acetylcholine, dopamine, noradrenaline 
and serotonin (Fredholm et al., 1988). In particular, a powerful suppression of glutamate release 
from presynaptic terminals has been described in the hippocampus (Corradetti et al., 1984; 
Burke et al., 1988). 
At post-synaptic level, A1 receptors mediate a direct hyperpolarization of neurones via 
activation of G-protein-coupled inwardly rectifying potassium (GIRK) channels (Kir 3.2 and 
3.4 channels) (Takigawa et al., 1999, 2002) and by a direct increase of Cl- conductance (Greene 
et al., 1991) thus, stabilizing the membrane potential. 
Out from CNS, high levels of A1 receptor expression are found in adrenal glands, eye and atria. 
Intermediate levels are found in skeletal muscles, liver, kidney, adipose tissue, gastrointestinal 
smooth muscles and bronchi. Lung and pancreas present low level of A1 receptor expression 
(Fredholm et al., 2001). 
 
Pharmacology  
Selective agonists for the A1 receptor have been synthesized from adenosine molecule by 
modifications on its purine ring or its ribose. By substitution of adenosine in N6 position CPA 
(N6-cyclopentyladenosine), a compound with greater affinity for A1 receptor, has been 
obtained. Its derivative CCPA (2-chloro-N6-cyclopentyladenosine) presents a slightly higher 
affinity for A1 receptor in human, rats and mouse tissues and is active at nanomolar 
concentrations. Further agonist for A1 receptor analogues of adenosine are CADO (2-
chloroadenosine), L-PIA ((R)-N-(1-methyl-2-phenylethyl) adenosine), CHA (N(6)-
cyclohexyladenosine) and R-PIA (N6-R-phenylisopropyladenosine) (Jacobson et al., 1992). 
Allosteric enhancers for this receptor subtype are also available such as PD81,723 (2-amino-3-
benzoylthiophene) and analogues. The discovery and development of pyridine-based non-
nucleoside agonists of the adenosine receptors started from the publication of patents from 
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Bayer describing pyridine derivatives endowed with agonist activity at the adenosine receptors. 
One of these compounds is the adenosine A1 receptor agonist 2-amino-6-[[2-(4-chlorophenyl)-
1,3-thiazol-4-yl] methylsulfanyl]-4-[4-(2-hydroxyethoxy) phenyl] pyridine3,5-dicarbonitrile, 
also named BAY68-4986 or Capadenoson. Capadenoson, currently classified as 
an adenosine A1 receptor partial agonist, has undergone two phase II clinical trials, initially in 
patients with atrial fibrillation and subsequently in patients with stable angina (Tendera et al., 
2012). Structural modifications at the exocyclic amine group of Capadenoson led to the 
development of the adenosine A1 receptor agonist 2-(((2-(4-chlorophenyl)-1,3-thiazol-4-
ylmethyl) sulfanyl)-4-(4-(2-hydroxyethoxy) phenyl)-6-(pyrrolidin-l-yl) pyridine-3,5-
dicarbonitrile, also named Neladenoson. Like Capadenoson, Neladenoson is a selective partial 
agonist at the A1 receptor (Meibom et al., 2017; Voors et al., 2017). Neladenoson showed in rat 
preclinical models cardioprotective effects analogous to Capadenoson, although with lower 
central effects. Methylxanthines are non-selective antagonists of adenosine receptors (Sattin et 
al., 1970). Antagonists with high affinity have been synthesized from theophylline, by 
substitution in position 8 with a cycloalkyl group (e.g. compounds 8-CPT, 8-
cyclopentyltheophilline and 8-PT, 8-phenyltheophilline). By substitution of the methyl groups 
in 8-CPT with propyl groups DPCPX (8-Cyclopentyl-1,3-dipropylxanthine), a selective 
antagonist for A1 receptor with high affinity, has been synthetized (Bruns et al., 1987). The 
substitution of the propyl group in position 3 of DPCPX with a more complex group led to the 
synthesis of BW-A884U (3-(4-Amino)phenethyl-1-propyl-8-cyclopentylxanthine) (Patel et al., 
1988), a compound more selective than DPCPX. Other derivatives as KFM 19 (8-(3-
oxocyiclopentane)-1,3-dipropylxanthine), KW-3902 (Rolofylline; 8-(Hexahydro-2,5-
methanopentalen-3a(1H)-yl)-3,7-dihydro-1,3-dipropyl-1H-purine-2,6-dione), KF 15372 (8-
dicyclopropylmethyl-1,3-dipropylxanthine) and ENBX (1,3-dipropyl-8-endonorbornyl- 
xanthine), poorly soluble in water, were obtained from theophylline performing substitutions 
in position 8 (Jacobson et al., 1992). 
 
1.4.2 A2A Receptor: molecular structure, distribution and function 
A2A receptor is a glycoprotein of approximately 45 kDa with an amino acid sequence highly 
conserved with a homology of 90% between different species.  
Its intracellular section is particularly extended (412 amino acids in 4 loops) and it seems to be 
involved in several responses A2A-mediated (Cristalli et al., 2008). The receptor is associated 
to a Gs protein at TM2 and TM3 loops (Moreau et al., 1999), it stimulates adenylate cyclase 
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and increases intracellular cAMP concentrations (Moreau et al., 1999) and mobilizes the 
intracellular Ca2+ (Mirabet et al., 1997) (Figure 6).  
 
 
 
Figure 6. Overview of adenosine A2A receptor (A2AAR) intracellular signaling pathways. A2AAR 
stimulation increases adenylate cyclase (AC) activity, cAMP production, protein kinase A (PKA), and 
cAMP-responsive element-binding protein (CREB) phosphorylation. AKT and mitogen- activated 
protein kinases p38, ERK1/ 2 and JNK1/2 are activated following by A2AAR recruitment. Modified from 
(Borea et al., 2018). 
 
A2A receptors are expressed throughout all the CNS (Dixon et al., 1996). They are principally 
located in the basal ganglia: in the caudate-putamen, nucleus accumbens and olfactory tubercle 
(Jarvis et al., 1989; Rosin et al., 1998). In particular, this receptor subtype is expressed on 
striatopallidal GABAergic-enkephalin neurones (where it co-localises with dopamine D2 
receptors, but not on GABAergic-dynorphin striatal neurones (Fredholm et al., 2003 b). High 
levels of adenosine A2A receptor mRNA have been found in striatum (Schiffmann et al., 1991; 
Svenningsson et al., 1997), while lower levels have been found in hippocampus and cortex 
(Dixon et al., 1996; Svenningsson et al., 1997). Besides post-synaptically, A2A receptors are 
also located pre-synaptically on different GABAergic, cholinergic, glutamatergic neuron types 
(Hettinger et al., 2001; Rosin et al., 2003). In the CNS they are also expressed on astrocytes 
(Biber et al., 1999; Lee et al., 2003), microglia (Pedata et al., 2014), oligodendrocytes (Stevens 
et al., 2002), blood cells and vasculature (Phillis, 2004). 
In recent years, particular interest has been dedicated to study receptor dimerization, either in 
homomeric and heteromeric structures, since this phenomenon seems to frequently occur in 
numerous cell types and can modify the pharmacological profile of receptors and their 
functional role. Various lines of evidence indicate that such an interaction occurs post-
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synaptically in the striatum between A2A adenosine and D2 dopamine receptors, this 
heterodimerization inhibits D2 receptor functions (Ferre et al., 1991). While A1 receptor and 
A2A receptor heteromers are located pre-synaptically in glutamatergic terminals of the striatum 
(Ciruela et al., 2006), exerting opposite effects on the modulation of glutamate release through 
a “concentration-dependent switch” mechanism by which low adenosine concentrations inhibit, 
while high concentrations stimulate, glutamate release (Ciruela et al., 2006). 
In the nervous system, A2A receptor activation mediates excitatory actions, contrary to the A1 
receptor that exerts synaptic inhibition (Pedata et al., 1984; Spignoli et al., 1984; Latini et al., 
1996 c; Sebastião et al., 1996). Electrophysiological investigations about the role of A2A  
receptors under physiological conditions have shown that they increase synaptic 
neurotransmission. In fact, the A2A receptor Gs-mediated signalling increases cAMP level, a 
second messenger that activates protein kinase A (PKA) (Gubitz et al., 1996). PKA 
phosphorylates the Ca2+ channels of P type and thus, directly modulates the mechanisms of 
vesicle release. Vesicle exocytosis can also be regulated by βγ subunits of the Gs protein, which 
can promote the phosphorylation, mediated by PKC, of Ca2+ channels of N-type (Gubitz et al., 
1996; Gonçalves et al., 1997). In fact, in the hippocampus in vitro, A2A receptor stimulation 
results in a Ca2+-dependent release of acetylcholine (Spignoli et al., 1984; Cunha et al., 1995). 
Moreover, the selective stimulation of adenosine A2A receptors augments the amount of 
glutamate released in hippocampus and striatum of young rats (Popoli et al., 1995; Corsi et al., 
1999, 2000), supporting the theory about that A2A receptors increase excitatory amino acid 
release.  
A2A receptor also impacts in long-term potentiation (LTP), a form of synaptic plasticity 
associated with memory, central for learning process, that is increased by A2A receptor 
activation (Almeida et al., 2003). In fact, a decreased LTP in the nucleus accumbens was found 
in knock-out (KO) mice for the A2A receptor (d’Alcantara et al., 2001). 
It is worth noticing that the role of A2A receptors in the striatum is recently gaining interest in 
light of their heterodimerization with D2 dopamine receptors. The association between A2A and 
D2 receptors results in an antagonistic interaction which provided a rationale for evaluating 
A2A-selective antagonists in Parkinson’s disease. It was suggested that A2A antagonists not only 
provide symptomatic relief but also decelerate dopaminergic neuron degeneration in patients 
(Xu et al., 2005). On July 2019, A2A antagonists have been approved in the United States by 
FDA (Food and Drug Administration) in the therapy of Parkinson’s disease (fda.gov) 
(Takahashi et al., 2018). 
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A2A receptors are also highly present in spleen, thymus, immune cells both on cells of innate 
(macrophages, mast cells, monocytes, dendritic cells, and granulocytes) and on cells of adaptive 
(lymphocytes) immunity (Haskó et al., 2008; Antonioli et al., 2014). Lower levels are also 
found in the heart, lung and blood vessels (Fredholm et al., 2001). 
 
 
Pharmacology  
Most of A2A receptors agonists have been obtained from the adenosine molecule by substitution 
of the purine ring in the position 2 or by different types of substitutions at the ribose ring. By 
the replacement of an alchilamide group in position 5' of the ribose ring the agonists NECA (5'-
N-ethylcarboxamidoadenosine) and CGS21680 have been synthetized. NECA was long 
considered to be a selective A2 agonist but it has been largely demonstrated that it is an 
unselective agonist to all P1 receptors, with a slightly preference for A2A subtype. However, 
based on evidence that 2-substitution of NECA molecule increased selectivity, CGS21680 was 
developed as an A2A selective agonist. This compound is less potent and selective in humans 
than in rats, but it has been replaced by another recently developed A2A agonist, ATL-146e (4-
(3-[6-amino-9-(5-ethylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-
2-ynyl)-cyclohexanecarboxylic acid methyl ester), which is 50 fold more potent than 
CGS21680 for the human A2A receptor by substitution in position N6, the compound DPMA 
has been obtained (Bridges et al., 1988). 
Many of A2A receptor antagonists have been developed from the caffeine (1,3,7-
trimethylxanthine) molecule. DPMX (1,3-dipropyl-7-methyl-xanthine) and 8-cicloesilcaffeine 
are low selective A2A receptor antagonists (Williams et al., 1991). CSC (Jacobson et al., 1993) 
and KF17837 ((E)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine) (Nonaka et al., 
1994) are more selective but less easy to use since undergo to photoisomerization. Among the 
numerous A2A antagonists, the most selective so far are SCH58261 (7-(2-phenylethyl)-5-
amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolol[1,5-c]pyrimidine) and SCH442416 (2-(2-
Furanyl)-7-[3-(4-methoxyphenyl)propyl]-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-
5-amine) and the structurally related ZM241385 (4-(-2-[7-amino-2-{2-
furyl}{1,2,4}triazolo{2,3-a}{1,3,5}triazin-5-yl amino]ethyl)phenol). SCH58261 does not 
derive from xanthine, as well as CP66713 (8-chloro-1-phenyl- [1,2,4] triazolo[4,3-a] 
quinoxalin-4-amine). However, also CP66713 presents a good selectivity for the A2A receptor 
(Sarges et al., 1990). 
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1.4.3 A2B Receptor: molecular structure, distribution and function 
The A2B receptor is a glycoprotein of approximately 36-37 kDa, coupled to Gs protein, that 
stimulates adenylate cyclase, intracellular Ca2+ mobilization (Mirabet et al., 1997) and activates 
PKC and PLC (Abbracchio et al., 1995; Feoktistov et al., 1997). 
 
 
Figure 7. Overview of adenosine A2B receptor (A2BAR) intracellular signaling pathways. A2BAR 
stimulation increases adenylate cyclase (AC) activity, cAMP production, and protein kinase A (PKA) 
phosphorylation. A2BAR enrollment activates phospholipase C (PLC)-β and increases Ca2+. Mitogen-
activated protein kinases p38, ERK1/2, and JNK1/2 phosphorylation are induced by A2BAR activation. 
Modified from (Borea et al., 2018). 
 
A2B receptors are expressed both in the CNS and in the peripheral nervous system (PNS) (Dixon 
et al., 1996). A2B receptors are shown to be ubiquitously distributed in the brain and their mRNA 
has been detected in all rat cerebral areas studied with a prevalent presence on hippocampal 
neurons (Mogul et al., 1993; Kessey et al., 1997)  and on glial cells (Peakman et al., 1994; 
Fiebich et al., 1996). 
At peripheral level, A2B subtype is particularly abundant in the gastrointestinal tract, mainly in 
caecum, colon, urinary bladder, lung, blood vessels and adipose tissue (Fredholm et al., 2001). 
Increasing evidences indicate a role for this receptor in the modulation of inflammation and 
immune responses in selected pathologies like cancer, diabetes, as well renal, lung and vascular 
diseases (Borea et al., 2018). 
A2B receptors appear to induce the release of excitatory amino acids and acetylcholine, while 
they reduce the release of γ-amino butyric acid (GABA) in rat cortex (Phillis et al., 1993). In 
addition, at hippocampal level, they modulate the LTP process (Kessey et al., 1997). The 
signaling pathways generated by A2B receptors stimulation are strongly influenced by the 
signaling of other receptors that affect the PLC-Ca2+-PKC pathway. In brain slices, cAMP 
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accumulation due to the activation of the A2B receptor, is markedly increased by drugs that 
stimulate PKC (Fredholm et al., 1987; Hollingsworth et al., 1985).  
 
Pharmacology 
A class of non-adenosine A2B agonists with affinity values in the low nanomolar range has been 
synthesised by Beukers and colleagues as pyridine derivatives (Beukers et al., 2004). Among 
them the most important are LUF5834 (2-amino-4-(4-hydroxyphenyl)-6-(1H-imidazol-2-
ylmethylsulfanyl)pyridine-3,5-dicarbonitrile) (Beukers et al., 2004) and BAY60-6583 (2-[[6-
Amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]-2-pyridinyl]thio]-acetamide) (Kuno et 
al., 2007; Eckle et al., 2008 a) that are highly selective. LUF5835 (2-amino-4-(4-
hydroxyphenyl)-6-(1H-imidazol-2-ylmethylsulfanyl) pyridine-3,5-dicarbonitrile,17) is a full 
agonist with an EC50 of 10 nM for human A2B receptor expressed in CHO cells. 
Several potent and relatively selective antagonists have been found among anilide derivatives 
of xanthines with Ki values in the low nanomolar range, such as MRS 1754 (N-(4-
Cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-
acetamide) (Ji et al., 2001), that is over 200-fold selective for A2B versus all other adenosine 
receptors (Kim et al., 2000) and the selective A2B antagonist 8-[4-[4-(4-Chlopehenzyl) 
piperazide-1-sulfonyl) phenyl]]-1-propylxanthine (PSB603) (Fusco et al., 2018). 
Further antagonists xanthine-derived are MRE 2029-F20 (N-(2H-1,3-benzodioxol-5-yl)-2-{[5-
(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3yl] 
oxy}acetamide) and OSIP339391 (N-[2-[[2-phenyl-6-[4-(3-phenylpropyl) piperazine-1-
carbonyl]-7H-pyrrolo[3,2-e]pyrimidin-4-yl]amino]ethyl]acetamide) (Kim et al., 2001; Stewart 
et al., 2004; Gessi et al., 2005). 
 
1.4.4 A3 receptor: molecular structure, distribution and function 
A3 receptor is a protein of approximately 39 kDa, coupled to Gi protein. It evokes the same 
effects mentioned for A1 receptor (Englert et al., 2002), induces Ca2+ mobilization (Englert et 
al., 2002; Shneyvays et al., 2004, 2005) and interacts with MAPKs (Schulte et al., 2003) (Figure 
8).  
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Figure 8. Overview of adenosine A3 receptor (A3AR) intracellular signaling pathways. A3AR 
stimulation triggers decrease of adenylate cyclase (AC) activity and cAMP production, activation of 
glycogen synthase kinase-3β (GSK-3β), and consequent decrease of β -catenin, cyclin D1, and c-Myc. 
Increase induced by A3AR activation of phospholipase C (PLC)- β and Ca2+, as well as of RhoA and 
phospholipase D (PLD) is shown. Mitogen-activated protein kinases p38, ERK1/2, and JNK1/2 
phosphorylation are induced by A3AR activation. Modified from (Borea et al., 2018). 
 
The expression of A3 adenosine receptor in the brain is generally lower than that of the other 
subtypes (Ji et al., 1994) and is highly species-dependent (Fredholm et al., 2000, 2001). By the 
sensitive technique of real time PCR, A3 receptors are found in both neuronal and non-neuronal 
elements, i.e. astrocytes, microglia, and vasculature of the cerebral tissue (Zhao et al., 1997) 
with widespread distribution. In the rat, a significant expression of A3 receptors is found in 
cerebellum and hippocampus (Dixon et al., 1996) where they are mainly expressed at the 
presynaptic level (Lopes et al., 2003). 
In literature discrepancies about the role of adenosine A3 receptors in the CNS are present. An 
excitatory role of A3 receptor has been supported by evidence indicating that, in the rat 
hippocampus, its activation attenuates long-term depression (LTD) and allows induction of 
LTP elicited by a subliminal weak-burst protocol (Costenla et al., 2001). Additional evidence 
for an excitatory role of adenosine A3 receptors came from studies carried out in hippocampal 
slices (Pugliese et al., 2007). In the same brain area, A3 receptor activation through a selective 
agonist has been shown to antagonize the adenosine A1 receptor-mediated inhibition of 
excitatory neurotransmission (Dunwiddie et al., 1997). However, further electrophysiological 
studies refused this hypothesis, since several authors demonstrated that no significant 
interaction between A1 and A3 receptors occurs in the rat cortex and hippocampus (Brand et al., 
2001; Lopes et al., 2003) . Conversely, an inhibitory action has been attributed to A3 receptors 
by Brand and colleagues, who demonstrated that, in rat cortical neurons, the selective activation 
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of A3 receptor is involved in inhibition of excitatory neurotransmission, suggesting a synergic 
action with the inhibitory effect mediated by A1 receptor activation.  
Despite results obtained by A3 receptor stimulation, evidence that selective block of A3 
receptors does not affect neurotransmission in the CA1 region of the hippocampus under 
normoxic conditions, indicates that endogenous adenosine at physiological concentration does 
not exert tonic activation of A3 receptors (Dunwiddie et al., 1997; Pugliese et al., 2003).  
In the periphery, A3 subtype is mainly found in rat testis (Meyerhof et al., 1991) and mast cells, 
in accordance with the fact that for a long time the unique role assigned to this receptor have 
been mast cell degranulation and histamine release. Intermediate levels are found in the lung, 
spleen, thyroid and liver. Interestingly, A3 receptor is overexpressed in several cancer cells and 
tissues and is therefore likely to have an important antitumoral role (Borea et al., 2014). 
 
Pharmacology 
The most widely used A3 agonist is Cl-IB-MECA (2-Chloro-N6-(3-iodobenzyl)-adenosine-5′-
N-methyluronamide) for its high affinity (low nanomolar range) and selectivity (more than 100-
fold versus A1 and A2A receptors) towards A3 receptors. For these features Cl-IB-MECA is the 
most used pharmacological tool to investigate A3-mediated effects. Cl-IB-MECA affinity does 
not vary beyond an order of magnitude among mammal species. The new, highly selective, A3 
agonist (1S,2R,3S,4R,5S)-4-(2-((5-chlorothiophen-2-yl)ethynyl)-6-(methylamino)-9H-purin-
9-yl)-2,3 dihydroxy-N-methylbicyclo [3.1.0]hexane-1-carboxamide (MRS5980) was 
synthesized as reported previously (Tosh et al., 2014; Fang et al., 2015). 
Particularly potent agonists can be obtained through the 4'-thio modification of adenosine 
derivatives, such as in LJ 568 (Jeong et al., 2003). 
An emblematic feature of the adenosine A3 receptor is its insensitivity to the antagonistic 
actions of methylxanthines, such as caffeine and theophylline, the traditional blockers of 
adenosine receptors. Hence, A3 antagonists are dihydropyridines, pyridines and flavonoids. 
Another class of highly selective compounds are isoquinoline and quinazoline derivatives, such 
as VUF5574 (N-(2-methoxyphenyl)-N′-[2-(3-pyrindinyl)-4-quinazolinyl]-urea) that presents a 
Ki value of 4 nM versus human A3 receptors but not versus the rat isoform. In this regard, it is 
worth noticing that significant species differences in the affinity of adenosine A3 receptor 
antagonists have been noted, as expected from the high structural inter-species variability 
already mentioned. The affinity values of several A3 blockers are typically more than 100-fold 
greater on human than rat receptors, as described for MRS1220 (N-[9-Chloro-2-(2-furanyl) 
[1,2,4]-triazolo[1,5-c] quinazolin-5yl] benzene acetamide).  
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Among the antagonists are also CCPA and DPMA (N(6) -[2-(3,5-dimethoxyphenyl)-2-(2-
methylphenyl)-ethyl]adenosine), whose structures have been used to get the drug MRS1292 
which is a selective antagonist of A3 receptors, both in rat and in humans (Gao et al., 2002; 
Yang et al., 2005). At least, selective adenosine antagonist is MRS1523 (3-propyl-6-ethyl-5-
[(ethylthio) carbonyl]-2 phenyl-4-propyl-3-pyridine carboxylate). 
 
Role of adenosine in oligodendrocyte precursor maturation 
 
1.5 Oligodendrogenesis  
Oligodendrocytes are neuroglial cells responsible, within the central nervous system, for myelin 
sheath formation that provides an electric isolation of axons and accelerates the transmission of 
electric signals. In order to be able to produce myelin, oligodendroglial cells progress through 
a series of highly regulated differentiation steps from oligodendrocyte precursor cells (OPC) to 
mature oligodendrocytes (OLG) (Barateiro et al., 2014).  
OPC are generated during embryonic development in restricted areas, such as the subventricular 
zone (SVZ), and present an amazing migration capacity that allow them to spread and populate 
brain and spinal cord (El Waly et al., 2014). During maturation oligodendroglial cells lose their 
capacity to migrate and proliferate (Barateiro et al., 2014) and acquire an elaborate morphology 
with many branched processes, that wrap around axons and form membrane sheaths of myelin, 
typical of mature OLG (De Castro et al., 2005).  
During embryonic development oligodendrocytes are the last cells to be generated after neurons 
and astrocytes. In vivo, differentiation and maturation of oligodendroglial cell are postnatal 
processes. Rodents (rat and mouse) at postnatal day 2 (P2) present mainly preoligodendrocytes 
and myelination of the CNS starts only at P7 (Dean et al., 2011).  
Oligodendrocyte maturation involves a sequence of cellular transitions: distinct phases of 
oligodendrocyte maturation can be identified by stage-specific morphological changes and by 
the expression of stage-specific surface antigens (Raff et al., 1983; Goldman et al., 1986; Levi 
et al., 1986; Gard et al., 1989; Gallo et al., 1995). It has been observed that the expression of 
different markers is related to morphological changes of the cell (Fumagalli et al., 2011). This 
phenomenon has allowed a classification into four stages of differentiation: oligodendrocyte 
precursor cell (OPC), preoligodendrocyte (or pre-OLG), immature (or pre-myelinating) OLG 
and mature, myelinating OLG (Barateiro et al., 2014) (Figure 9 A).  
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The initial stage of maturation (1-2 days in culture), show a bipolar (or tripolar) morphology, 
typical of OPC (stage 1). OPC are proliferative cells with great migratory capacity and express 
defined surface antigens, marker of precocious maturation stages, such as platelet-derived 
growth factor receptor α (PDGFRα), chondroitin sulfate proteoglycan nerve-glial antigen 2 
(NG2) and transcription factor Olig2 (Pringle et al., 1992; Nishiyama et al., 1996; Ligon et al., 
2006). When OPCs start to differentiate in pre-OLG (stage 2), they are characterized by 
emerging secondary ramifications and by the expression of intermediate molecular markers 
such as, GPR17 protein (Boda et al., 2011) and O4 antigen (Sommer et al., 1981). At 
approximately day 6 in culture, they acquire the typical phenotype of immature oligodendrocyte 
with highly branched morphology (stage 3) (Fumagalli et al., 2011). The expression of the 
intermediate markers GPR17 and O4 persists while early markers such as NG2 and PDGFRα 
are downregulated (Yu et al., 1994). Finally, at approximately day 10 in culture, when 
oligodendrocytes reach the mature myelinating stage (OLG), they acquire immunoreactivity for 
myelin specific structural proteins such as MAG (myelin associated glycoprotein) and MBP 
(myelin basic protein) (stage 4) (Fumagalli et al., 2011) (Figure 9 B). 
 
             
               A           
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Figure 9. Characterization of the stages of differentiation of oligodendroglial cells. Oligodendrocyte 
maturation involves a sequences of distinct phases with distinct morphological characteristics (A) From 
(Fumagalli et al., 2011) and express a defined antigenic pattern (B) From (De Castro et al., 2005).  
 
During their maturation, oligodendrocyte lineage cells display different functional voltage-
gated ion channels (Sontheimer et al., 1989) including both inward and outward rectifying K+ 
channels (Sontheimer et al., 1988; Williamson et al., 1997), Na+ channels (Barres et al., 1990), 
and different subtype of Ca2+ channels (Verkhratsky et al., 1990; Berger et al., 1992). Immature 
OPCs (NG2+) show outward membrane currents whose main component is represented by 
delayed rectifying K+ currents (IK) (Gallo et al., 1996) characterized by low time- and voltage-
dependent inactivation and by a threshold of activation at about -40 mV. On the contrary, 
another K+ conductance typical of undifferentiated OPCs, the transient outward current (IA), 
presents a rapid time-dependent inactivation (approximately 50 ms) and a voltage-dependent 
inactivation at potentials above -40 mV (Gallo et al., 1996). At this immature stage a 
subpopulation (about 60%) of OPCs also possess an inward sodium current (INa) tetrodotoxin-
sensitive, characterized by a rapid time-dependent inactivation (less than 1 ms) and a peak of 
amplitude that is evoked at around -10 mV (Káradóttir et al., 2008), never observed in mature 
stage (Coppi et al., 2013 a). 
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During development membrane outward K+ conductances (both IK and IA) undergo to a strong 
downregulation up to almost completely disappear in mature stages (Sontheimer et al., 1989; 
Barres et al., 1990; Gallo et al., 1996; Attali et al., 1997; Coppi et al., 2013 a). 
In parallel with outward K+ current downregulation, there is a gradual increase of inward 
rectifier K+ currents (Kir), activated at potentials more negative than membrane resting potential 
(Vm), which are the main conductances represented in mature OLs (Knutson et al., 1997). 
Among the mentioned currents, those associated with voltage-gated K+ channels, such as IK, IA  
and Kir are involved in the regulation of oligodendrocyte differentiation and thus of myelin 
formation (Sontheimer et al., 1989; Gallo et al., 1996). In addition, the expression of IK currents 
is linked to cell cycle regulation and hence to proliferative capacity of OPC (Chittajallu et al., 
2005) because of the following: (1) a downregulation of IK occurs as oligodendrocyte lineage 
cells mature (Sontheimer et al., 1989; Barres et al., 1990); (2) proliferative OPCs express larger 
IK currents than cell cycle-arrested OPCs (Knutson et al., 1997; Chittajallu et al., 2002); (3) 
pharmacological block of IK induced by tetra-ethyl-ammonium (TEA) in cells belonging to the 
oligodendrocyte lineage, is sufficient to delay proliferation and differentiation (Gallo et al., 
1996; Chittajallu et al., 2002). Hence, treatments finalized to modulate these currents may affect 
oligodendrocyte proliferation and differentiation.  
It has been demonstrated that a small fraction of OPCs generated during development are 
maintained in an immature and slowly proliferative or quiescent state in the adult CNS (Dawson 
et al., 2003) where they are called “adult OPCs”. These adult OPCs are present in all brain 
structures and represent 2-9% of the CNS cellular population (Dawson et al., 2003), however, 
they are the largest population of proliferating cells within the CNS (Horner et al., 2000). The 
adult OPC population persists stable in the adult CNS (Rivers et al., 2008) where they represent 
an endogenous reservoir of immature cells (De Castro et al., 2005), constantly produced by 
neural stem cells located in the SVZ (Menn et al., 2006). Current evidences suggest that adult 
OPCs express the same markers (e.g. NG2 or PDGFRα) and appear morphologically similar to 
their developmental counterpart (Franklin et al., 2008).  
Very little is known about factors that control adult oligodendrogenesis. Upon opportune 
stimuli both physiological (e.g. voluntary physical exercise; (Simon et al., 2011)) and 
pathological (e.g. injury, inflammation, demyelination), adult OPCs are able to react with 
increased proliferation and subsequent differentiation in mature oligodendrocytes (Simon et al., 
2011), thus representing the primary source of myelinating cells (Nishiyama et al., 1999; 
Windrem et al., 2004).  
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Self-renewal and multipotential features of OPCs have been reported. Thanks to their self-
renewal features, adult OPCs continue to proliferate throughout life span (Young et al., 2013) 
and to differentiate in mature OLG, ensuring myelin integrity. Furthermore, under specific 
conditions, adult OPCs give rise to neurons, astrocytes (Nishiyama et al., 1999) and Schwann 
cells (Zawadzka et al., 2010). This potentiality of OPCs is still to be confirmed since remains 
controversial due to some discrepancy between in vitro and in vivo data (Crawford et al., 2014). 
Adult OPCs have shown to contact the axonal membrane (Butt et al., 1999) and the synaptic 
terminals (Ong et al., 1999). This raises the question of whether adult OPCs may be capable to 
impact or to react to neuronal activity (Butt et al., 2002; Nishiyama et al., 2002). Concerning 
this topic a recent study demonstrated the positive impact of neuronal activity on myelination 
in the adult brain (Gibson et al., 2014). 
 
1.6 Purinergic signaling in oligodendrogenesis 
Purinergic signaling has recently emerged as one of the most pervasive mechanism for 
intercellular communication in the nervous system, affecting communication between many 
types of neurons and all types of glial cells (Fields et al., 2006).  
In the CNS, neurons and multiple types of glia are in close proximity, so that a signal such as 
ATP released by a neuron could exert effects on many nearby cells (Figure 10). 
 
 
Figure 10. Schematic representation of the role played by extracellular nucleosides in modulating cell-
to-cell communication between neurons and glial cells in the central nervous system. ATP is 
exocytotically released from nerve terminals as a co-transmitter during synaptic transmission. 
Adenosine is generated by itself or through the activity of ecto-nucleotidases and further contributes to 
neurotransmission and to the modulation of glial cell functions. Astrocytes and microglia themselves 
can release ATP, which acts autocrinally or paracrinally on surrounding cells. An axonal non-vesicular 
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ATP release has been recently identified, which plays a fundamental role in controlling oligodendrocyte 
myelinating functions, and, possibly, also NG2+ cell activity and maturation. Modified from (Lecca et 
al., 2012).  
 
Concerning oligodendrocytes, it has been demonstrated that purines exert multiple effects 
including increased motility, proliferation and differentiation of cultured OPCs (Othman et al., 
2003; Agresti et al., 2005). 
Adenosine acts as a potent neuron-glial transmitter and by stimulation of its receptors can affect 
both the process of migration of OPCs and of myelination by mature OLs (Stevens et al., 2000, 
2002). Indeed OPCs express all adenosine receptors subtype (A1, A2A, A2B, A3); (Stevens et al., 
2002; Fredholm et al., 2011). 
To date, a functional role on migration of OPCs and on myelination by mature OLs has been 
attributed to the adenosine A1, A2A and A3 receptors (González-Fernández et al., 2014; Coppi 
et al., 2015). 
Adenosine, through the activation of the adenosine A1 receptors seems to be a primary activity-
dependent signal inhibiting the proliferation and promoting differentiation of pre-myelinating 
progenitors into myelinating oligodendrocytes (Stevens et al., 2002) and stimulating OPC 
migration (Othman et al., 2003). Coppi et al. (Coppi et al., 2013 b), showed that the selective 
activation of the adenosine A2A receptors decreases outward rectifying, sustained, IK currents 
and inhibits in vitro OPC differentiation towards mature, myelinating oligodendrocytes, 
without affecting cell division. Furthermore, oligodendrocytes apoptosis induced by adenosine 
A3 receptor activation was reported by Gonzales-Fernandez (González-Fernández et al., 2014). 
These adenosine roles may be important during development but also in pathological conditions 
such as ischemia, when extracellular adenosine concentrations in the brain increase (Latini et 
al., 2001) and could promote the migration of OPC toward the damaged tissue and the process 
of neuron remyelination.  
Identifying the molecular mechanisms which underlay oligodendrocyte development is not 
only critical to furthering our knowledge of oligodendrocyte biology, but also has implications 
for understanding the pathogenesis of demyelinating diseases such as multiple sclerosis (MS). 
For example, the observation that OPCs are present in MS lesions but fail to differentiate into 
mature oligodendrocytes (Levine et al., 1999; Chang et al., 2000) suggests that the 
remyelination process is blocked at a pre-myelinating stage in demyelinating lesions.  
Thus, identification of critical regulators that inhibit myelination/remyelination could facilitate 
the development of therapeutic targets for myelin repair in CNS demyelinating diseases. 
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To date, no evidence exists concerning the functional role of adenosine A2B receptor in OPC 
cells.  
 
The bioactive lipid mediator sphingosine 1-phosphate (S1P) has recently gained attention in 
myelination within CNS since its five receptors (S1P1-5) are found in oligodendroglial cells, 
where they regulate a number of processes, ranging from cell proliferation, and maturation to 
dendrite elongation (Jaillard et al., 2005; Jung et al., 2007; Miron et al., 2008).  
A recent study demonstrate an interaction between the adenosine A2B receptor and S1P pathway 
in human and mouse erythrocytes in vitro (Sun et al., 2015). 
 
1.7 Sphingosine kinase/Sphingosine 1-phoshate pathway 
Sphingosine-1-phosphate (S1P) is a sphingolipid signaling molecule that has been implicated 
in the control of a wide variety of processes, including cell growth, survival, differentiation, 
apoptosis, and cell migration (Maceyka et al., 2009). 
S1P is generated by ATP-dependent phosphorylation of sphingosine by the sphingosine kinase 
(SphK), an enzyme that exists in two isoforms with different subcellular distribution, SphK1 
and SphK2. Cellular levels of S1P are tightly regulated by the balance between its synthesis by 
SphK and its degradation by either hydrolysis to sphingosine by S1P phosphatases (Mandala et 
al., 2000; Le Stunff et al., 2002) or cleavage to trans-hexadecenal and ethanolamine phosphate 
by a S1P lyase (Van Veldhoven et al., 2000) (Figure 11). 
 
 
Figure 11. S1P pathway: enzymes involved in the production and degradation of S1P and its derivates. 
Modified from (O’Sullivan et al., 2017). 
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After generation, S1P can be exported out of the cell either by the specific transporter Snipster 
2 (Snps2) (Nijnik et al., 2012) or by several members of the ABC transporter family (Mitra et 
al., 2006). 
S1P exert extracellular functions through the binding to five S1P-specific G protein-coupled 
receptors, called S1P1-5 receptors (O’Sullivan et al., 2017). S1P receptors are expressed 
ubiquitously and play important roles in cell survival, growth and differentiation in many cell 
types, including cells of the immune, cardiovascular and central nervous system (CNS) (Toman 
et al., 2002; Terada et al., 2004; Kono et al., 2008) (Figure 12). 
 
 
Figure 12. G-protein coupled signaling through S1P receptors. Activation of S1P receptors transduce 
several well characterized signaling pathways. Modified from (O’Sullivan et al., 2017) . 
 
S1P1-3 are widely distributed in the immune and cardiovascular systems and the CNS; S1P1 is 
highly expressed on T and B lymphocytes (Mandala et al., 2002; Ishii et al., 2004). S1P4 is 
generally confined to lymphoid and hematopoietic tissues, and S1P5 is predominantly located 
in CNS white matter (Watterson et al., 2003; Sánchez-Moreno et al., 2004).  
S1P receptors modulation has emerged as an effective disease modifying therapeutic strate gy 
in multiple sclerosis (MS). Several oral agents are currently in development, including 
Fingolimod (FTY720), an immunosuppressant drug which is an analog of sphingosine. 
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1.8 Fingolimod 
Fingolimod, GilenyaR, 2-amino-2[2-(4-octylphenyl)ethyl]-1,3-propanediol) was originally 
synthesized by the Japanese chemist Tetsuro Fujita from Yoshitomi Pharmaceutical Industries 
Ltd. (present: Mitsubishi Tanabe Pharma Corporation, Japan) (Adachi et al., 1995) using the 
natural compound myriocin (ISP-1) as a lead.   
Fingolimod (FTY720) is converted in vivo by SphK2 to yield its active form, FTY720-
phosphate (FTY720-P) which is a structural analogue of sphingosine (Figure 13), a potent 
ligand of all S1P receptor except S1P2 receptor subtype.  
 
 
Figure 13. Phosphorylation of fingolimod generates a structural analog to S1P. Fingolimod shows high 
analogy to sphingosine and is phosphorylated by sphingosine kinases, mainly SphK2, which is the 
predominant SphK isoform in the brain. Fingolimod is a prodrug of fingolimod phosphate that can signal 
via S1P receptors and activate intracellular targets of S1P. Modified from (Brunkhorst et al., 2014). 
 
FTY720 has been shown to prolong the survival of allograft in different animal  (Chiba et al.,  
1996) and to induce protective effects in animal of autoimmune diseases (Mizushima et al., 
2004; Maki et al., 2005). Administration of FTY720 is highly efficacious in the MS model of 
experimental autoimmune encephalomyelitis (EAE), both were given at the time of 
immunization and at the onset of the symptoms (Fujino et al., 2003; Webb et al., 2004). 
The therapeutic effect of FTY720 in multiple sclerosis and in its animal model, experimental 
autoimmune encephalomyelitis (EAE), is attributed to the modulation of S1P1 receptor on 
lymphocytes. FTY720-P binds with high affinity to S1P1 receptor expressed on lymphocytes 
and is able to internalize and degrade it. This downregulation renders lymphocytes 
unresponsive to the normal S1P gradient and thus deprives them of the obligatory signal that 
would ordinarily allow them to egress from lymphoid tissues and recirculate to the periphery 
(Brinkmann et al., 2002, 2004; Mandala et al., 2002; Matloubian et al., 2004; Balatoni et al., 
2007; Brinkmann, 2007). 
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Oral fingolimod thus prevents normal egress of lymphocytes, which are retained in lymph 
organs and away from sites of inflammation (Mandala et al., 2002; Brinkmann et al., 2004; 
Matloubian et al., 2004). 
In addition, there is also evidence supporting the concept of anti‐inflammatory, glioprotective 
and neuroprotective actions of S1P receptors modulators in the CNS (Choi et al., 2011; Kim et 
al., 2011; Soliven et al., 2011). In vitro studies have demonstrated that FTY720‐P regulates the 
survival, differentiation and process dynamics of cultured rodent and human OLG lineage cells 
(Coelho et al., 2007; Jung et al., 2007; Miron et al., 2008 a). Furthermore, the treatment of mice 
with FTY720 protects against acute cuprizone‐induced OLG injury, demyelination and axonal 
loss but does not promote remyelination in this model. The protective effect of FTY720 in the 
cuprizone model may be mediated not only by direct actions on S1P receptors on OLGs, but 
also by indirect or anti‐inflammatory actions on astrocytes and microglia (Kim et al., 2011). 
FDA approval of fingolimod came in 2010, making this medication the first orally available 
effective treatment reducing the number of relapses and disease severity in relapsing -remitting 
multiple sclerosis. 
1.9 Effects of S1P signaling in the CNS. 
The role of S1P and its receptors in the CNS has been extensively investigated (Choi et al., 
2013) (see Table 2).  
 
 
Table 2. Functional S1P receptors expression in cells of the CNS. Modified from (O’Sullivan et al.,  
2017).  
 
Four of the five S1P receptors are found in the CNS (S1P1, S1P2, S1P3 and S1P5), with all four 
receptors expressed on neurons, astrocytes, microglia and oligodendrocytes (Figure 14). 
 
________________________________________________________________________________ Introduction 
31 
 
 
Figure 14. Distribution of S1P receptors subtypes on neural cells. From (Chun, 1999). 
 
In neurons S1P receptors are expressed in brain areas showing active neurogenesis (Chun, 1999; 
McGiffert et al., 2002; Harada et al., 2004), whereas KO mice with a constitutive genetic 
deletion of S1P1 showed defective neuronal development (Mizugishi et al., 2005).  
S1P has been shown to promote the migration of neural stem/progenitor cells toward areas of 
damage in the CNS via S1P1, which are abundantly expressed on neural stem/progenitor cells 
(Kimura et al., 2007). S1P signaling may also be neuroprotective, as suggested from data 
obtained from several different in vitro systems(Edsall et al., 1997; Shinpo et al., 1999; Chin et 
al., 2002). These observations suggest that receptor-mediated S1P signaling may be involved 
in promoting some aspects of neuronal injury repair.  
Astrocytes express S1P1, S1P2, S1P3 and S1P5, with S1P3 and S1P1 being expressed at greater 
levels than the other two receptors subtypes (Rao et al., 2003). 
When activated by pathological stimuli, S1P1 and S1P3 receptors are upregulated in activated 
astrocytes (Van Doorn et al., 2010), indicating that these receptor subtypes may be important 
in pathological processes.The results of various studies suggest that S1P can influence astrocyte 
proliferation, migration, and astrogliosis (Rao et al., 2003, 2004; Yamagata et al., 2003; 
Mullershausen et al., 2007; Miron et al., 2008 a). In vitro, S1P induced activation and 
proliferation of astrocytes, whereas in vivo, injection of S1P into the striatum of mouse brains 
induce astrogliosis (Sorensen et al., 2003). In addition, FTY720-P has been shown to affect S1P 
receptor-mediated signaling and migration of astrocytes in vitro (Mullershausen et al., 2007; 
Osinde et al., 2007). 
In microglia, the expression of S1P receptors appears to be dependent their activation states. 
Indeed, in activated microglia, S1P1 and S1P3 receptors are down-regulated but S1P2 receptor 
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is up-regulated (Choi et al., 2013). The S1P1 deletion in microglia has been shown to reduce 
activation of these cells in experimental autoimmune encephalomyelitis spinal cords, however 
the precise function of these receptors on microglia remains to be established (O’Sullivan et al., 
2017).  
 
1.9.1 S1P in oligodendrogenesis 
Remyelination has been documented to occur in human MS lesions and in animal models of 
MS. Remyelination is a complex mechanism requiring cellular processes of proliferation, 
migration, adhesion, process extension/retraction, and differentiation (Miron et al., 2008).  S1P 
signaling has significant effects on these processes in oligodendrocytes (Saini et al., 2005; 
Novgorodov et al., 2007; Miron et al., 2008). S1P5 and the S1P1 receptors are both expressed 
on oligodendrocytes, and their relative levels of expression seem to depend on the 
developmental stages of the cell (McGiffert et al., 2002; Miron et al., 2008).  
In particular, mature OLG express S1P5 and at lesser extent S1P1 S1P2 and S1P3, whereas OPC 
express at a higher level S1P1 than S1P2, S1P3 and S1P5 receptors (Yu et al., 2004; Jung et al., 
2007; Novgorodov et al., 2007). In vitro studies demonstrated that FTY720-P differently 
modulates differentiation, proliferation migration and availability of OPCs and/or OLGs relying 
on the activation of different S1P receptors subtypes whose expression depends upon the 
developmental stage of OPCS (Jung et al., 2007). Furthermore, it protects from myelin damage 
in EAE model and chronic progressive CNS inflammation (Kataoka et al., 2005; Rothhammer 
et al., 2017).  
 
Cerebral ischemia and role of adenosine receptors 
 
1.10 Cerebral ischemia 
Stroke is a form of cerebrovascular disease which affects blood supply to the brain.  
World Health Organization (WHO) defines stroke as “rapidly developed signs of focal (or 
global) disturbance of cerebral function lasting longer than 24 h (unless interrupted by death), 
with no apparent non vascular cause” (Aho et al., 1980).  
Stroke, being the second leading cause of death (Dariush et al., 2015) and third leading cause 
of disability (Murray et al., 2012), is considered as major health problem worldwide. Factors 
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like diabetes, hypertension, hypercholesterolemia, smoking and alcohol abuse have been 
associated with cardiovascular disease in general and stroke in particular.  
The neurological complications and clinical manifestations following a stroke vary 
considerably as well, depending upon which areas of the brain were affected and to what degree. 
Deficits after stroke can include depression, partial paralysis, difficulties with memory, 
thinking, language, and movements. 
Stroke can be classified into two basic types: ischemic stroke and hemorrhagic stroke (Figure 
15). 
 
Figure 15. Types of stroke. Modified from (Kumar et al., 2016).  
 
Ischemic stroke accounts for 80–87% of all cases (Sudlow et al., 1997; Dariush et al., 2015) 
and is caused by occlusion of a major cerebral artery by a thrombus or an embolism, which 
leads to loss of cerebral blood flow, a condition of hypoxia and glucose deprivation (oxygen, 
glucose deprivation: OGD) and subsequently tissue damage in the affected region (Gibson, 
2013). 
Hemorrhagic stroke accounts for about 13-20% of the total stroke cases (Sudlow et al., 1997; 
Dariush et al., 2015). This type of stroke can be subarachnoid or intracerebral and originate with 
the rupture of a cerebral blood vessel or an aneurysm within the blood vessel, resulting in an 
accumulation of blood and compression of brain tissue (Sacco et al., 1989, 1997; Levine, 2004). 
Ischemic brain injury results from a complex sequence of pathophysiological events that evolve 
over time and space (Figure 16).  
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Figure 16. Cascade of pathogenetic mechanisms after ischemia. Primary mechanisms of excitotoxic ity 
lead to acute cell death. Depolarization spreads in the periinfarct areas. In the following several hours, 
activation of resident immune cells, i.e. microglia and a cascade of production of inflammation 
mediators occur. Cell death/neurogenetic responses progress along days/weeks after ischemia. Figure 
modified from (Dirnagl et al., 1999).  
 
The major pathogenic mechanisms of this cascade include: primary acute mechanisms of 
excitotoxicity and peri infarct depolarizations followed by activation of resident immune cells, 
i.e microglia, and production or activation of inflammation mediators (Dirnagl et al., 1999). 
Proinflammatory cytokines, that upregulate cell adhesion molecules, exert an important role in 
promoting neutrophil infiltration and accumulation in brain parenchyma (Stoll et al., 1998; 
Huang et al., 2006). Although after ischemia precocious activation of immune cells may be 
neuroprotective and supportive for regeneration, protracted neuroinflammation is now 
recognized as the predominant mechanism of secondary brain injury progression.  
Following a focal stroke, the ischemic lesion can be divided in two distinct regions (Figure 17): 
the center of the ischemic area (ischemic core) in which the flow reduction is most pronounced 
and leads to rapid energy failure and cell death (Hossmann, 1994) and the surrounded area, the 
ischemic penumbra, where electrical functions are lost but energy metabolites and ion 
homeostasis are not significantly altered (Astrup et al., 1981). It is estimated that initially, the 
area of penumbra corresponds to 50% of the tissue that later will progress into infarct (Dirnagl 
et al., 1999). The understanding of mechanisms occurring in the penumbra zone is essential to 
preserve function and promote the survival of nervous cells after reperfusion. The main goal of 
a neuroprotective pharmacological treatment is to recover the area of ischemic penumbra from 
an irreversible neurodegeneration. 
________________________________________________________________________________ Introduction 
35 
 
 
Figure 17. The red area on the figure marks the infarcted core, a brain region of low perfusion in which 
cells have lost their membrane potential. The ischemic penumbra, marked by the remaining colors, is 
potentially salvageable if an appropriate treatment is administered within a specified therapeutic window 
in which intermediate perfusion prevails and identified as the salvageable brain area. Modified from 
(Dirnagl et al., 1999). 
 
Despite advances in the understanding of the pathophysiology of cerebral ischemia, therapeutic 
options for acute ischemic stroke remain very limited (Donnan et al., 2008). 
At the moment, the only drug approved to treat ischemia is the tissue plasminogen activator 
(tPA), a specific enzyme that cleaves proteins which are present in the blood, such as fibrin, an 
essential protein in blood clotting, and thrombi. The main issue is that in order to perform such 
a vital function tPA must be necessarily administered in the first 3-4 hours after the 
manifestation of the symptomatology. Because of its short therapeutic window and by its 
complication derived essentially from the risk of hemorrhage, the number of patients who might 
receive treatment and therefore potentially benefit is small (Donnan et al., 2008).  Drugs like 
aspirin, other antiplatelets, and anticoagulants are used as preventive therapy of stroke (Albers 
et al., 2011; Macrez et al., 2011). Consequently, the successful treatment of acute ischemic 
stroke remains one of the major challenges in clinical medicine. 
 
1.11 Pathobiology of ischemia 
Cerebral ischemia triggers a series of hemodynamic, biochemical and behavioural disorders. 
Initially, due to the decrease in blood flow, neurological functions are affected. Subsequently, 
the metabolic activity is suppressed in order to maintain the structural integrity of the cells 
(Hossmann, 1994). This leads to activation of several signalling pathways that may be 
neuroprotective or harmful towards the brain. These events that include excitotoxicity, ionic 
imbalances, oxidative stress, inflammatory reactions and inflammatory cascade, occur 
simultaneously and depend on the intensity and duration of the ischemic insult. 
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1.11.1 Changes in cellular homeostasis  
It is well known that brain tissue is highly vulnerable to ischemia, such that even transient loss 
of oxygen and glucose to the cerebral tissue may culminate in cellular death (Woodruff et al., 
2011). In contrast to other organs, brain tissue uses glucose as its only substrate for energy 
metabolism. Brain is unable to store energy, thus it requires a constant supply of oxygenated 
blood containing an adequate glucose and oxygen concentration to maintain its function and 
structural integrity (Markus, 2004).  
Low blood flow values caused by ischemia can induce electron chain transport failure and an 
enormous efflux of potassium ions into the extracellular space (Rama et al., 2012). Furthermore, 
as a consequence of the decrease in oxygen values, mitochondrial oxidative phosphorylation is 
interrupted, thus resulting in a rapid decline in cellular level of ATP (Katsura et al., 1994; 
Martin et al., 1994; Rama et al., 2012). Reduction in ATP level further stimulates the glycolytic 
metabolism of residual glucose and glycogen, which induce protons and lactate accumulation 
and lead to rapid intracellular acidification and further reduction in cellular ATP production 
(Martin et al., 1994). Indeed, it has been seen that the lactate content during ischemia rises to 
~20mM (normal conditions ~15-20mM), leading to a pronounced acidosis (Katsura et al., 
1999). The accumulation of lactic acid in ischemic brain may greatly disturb the normal H+ 
homeostasis, and it has been suggested that excessive lactic acidosis facilitates ischemic 
mechanisms leading to cerebral infarction (Plum, 1983). 
pH in the brain is maintained at approximately at 7.2 (Casey et al., 2010) thanks to a strong 
regulation by active (ion pump transport) and passive (ion channel transport, intracellular buffer 
solution) mechanisms (Casey et al., 2010). During stroke, extrusion of CO2 from the cell is 
limited by poor perfusion thus accumulation of CO2 in the intracellular space decreases the 
performance of the buffer solution and contributes to the reduction of pH (Ekholm et al., 1991). 
In addition, the reduction of glucose and oxygen supply leads to the depletion of glycogen and 
phosphocreatine (PCr; cellular energy reserves), which increases the production of hydrogen 
ions. The pH regulates diverse cellular processes (Busa et al., 1984) and modulates the activity 
of many enzymes and ion channels. There are two main mechanisms of acidosis-induced 
damage during ischemia: free radical formation and cell calcium metabolism. Free radicals are 
activated when ischemia is followed by recirculation (Traystman et al., 1991) contribute to 
tissue damage (Folbergrová et al., 1995) and low pH increases their production (Gebicki et al., 
1981; Bralet et al., 1992). Ca2+ concentration depends on the level of pH (Kristián et al., 1996). 
A change in this parameter may trigger apoptosis, which can occur for pH values of 
approximately 6.5 (Barry et al., 1992). Excessive production of H+ ions in the cell after stroke 
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is owing to two factors: consumption of ATP, glucose glycogen and PCr stores, and a high 
concentration of CO2 (Roberts, 1999). 
Brain pH alteration after ischemic damage have been well documented by Back and co-workers 
in a model of permanent MCAo, in which areas of acidification and alkalization can be detected 
in ischemic penumbra surrounding the markedly acid core (Back et al., 2000). 
 
1.11.2 Glutamate-mediate excitotoxicity  
Glutamate is the predominant excitatory transmitter in the mammalian CNS and acts at a range 
of different receptor types. Under normal conditions, neuronal and glial uptake systems 
maintain the extracellular concentration of glutamate at micromolar levels (Bralet et al., 1992). 
Under ischemic conditions, glutamate is massively released (initially mediated by vescicular 
release from nerve terminals, and later by reverse transport from astrocytes), reaching 
millimolar concentrations in the extracellular space.  
These concentrations of glutamate are neurotoxic, and substantial evidence now implicates the  
toxicity of glutamate (excitotoxicity) in the pathogenesis of neuronal death after ischemia.  
Extracellular glutamate accumulating under ischemic conditions overstimulates N-methyl-D-
aspartate (NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and 
kainate-type glutamate receptors, promoting an increased permeability to Na+, K+ and Ca2+ ions 
which further depolarize the cell membrane and through metabotropic receptors (mGluRs) 
cause the mobilization of Ca2+ from intracellular stores. It is thought that the majority of 
neuronal degeneration is due to the intense activation of NMDA receptors glutamate-mediated. 
The increased intracellular concentration of Ca2+ leads to the activation of proteases, lipases, 
phospholipases and endonucleases that determine the rupture of the plasma membrane, of the 
cytoskeleton and DNA fragmentation, bringing to neuronal degeneration. Moreover, an influx 
of Ca2+ via NMDA receptor, can determine mitochondrial dysfunction, caspase-3 activation 
through the action of calpain, and production of nitric oxide (NO) and reactive oxygen species 
(ROS) leading to neuronal death (Dobrek et al., 2011). 
Uncontrolled release of glutamate causes one of the early events after ischemia, the peri-infarct 
depolarization (Figure 16): a series of spontaneous depolarization waves that propagate from 
the ischemic core toward the penumbra area. Moreover, the glutamate accumulation leads to 
an excessive influx of Na+ and Ca2+ together with water, resulting in cytotoxic edema 
(Furukawa et al., 1997). It has been observed that the infarcted area extends with the number 
of depolarizations (Mies et al., 1993), thus, drugs able to reduce the number of depolarizations 
are also able to limit the extension of the infarct (Ohta et al., 2001; Lu et al., 2005). 
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1.11.3 Oxidative stress 
In cerebral ischemia the production of ROS is increased and during reperfusion ROS production 
is even accelerated due to cytotoxic events such as lipid peroxidation, protein oxidation and 
fragmentation of DNA (Crack et al., 2005). Furthermore, lipid membrane peroxidation by ROS 
generates toxic aldehydes that damage a large number of ion channels, transporters, and 
cytoskeleton proteins.  
The nervous tissue is too vulnerable to the action of free radicals because of some peculiarities, 
such as being rich in lipids and unsaturated fatty acids which may react with ROS to form 
peroxyl radicals that determine the lipid oxidation of the membrane of neurons (Porter, 1984). 
Additionally, the brain has low to moderate catalase, and glutathione activity which eliminate 
the hydrogen peroxidase (H2O2) reducing oxidation (Cooper et al., 1997). It has been 
demonstrated how the application of antioxidant enzymes can be effective in contrasting 
oxidative stress (Huang et al., 2001). For instance, superoxide dismutase (SOD) plays a 
protective role in ischemia (Noshita et al., 2001; Sugawara et al., 2002) and SOD1 over-
expression attenuates apoptosis (Saito et al., 2004). Also, melatonin is known for its 
neuroprotective effect in models of ischemia, due to its anti-oxidant properties and capability 
in eliminating free radicals (Tan et al., 2000; Pei et al., 2002).  
The free radical, NO, is synthetized by the enzyme NO synthase (NOS) that is heavily activated 
during ischemia, as well as during reperfusion. The NO has neuroprotective and neurotoxic 
properties. The activation of NOS during the ischemia causes the death of neurons by 
combining with a superoxide yielding peroxynitrite (ONOO⁻), a potent radical which is an 
irreversible inhibitor of mitochondrial function in addition to being a pro-oxidant that damages 
lipids, proteins and DNA and increases glutamate release determining neuronal cell death (Radi 
et al., 1991). Conversely, the activation of NOS in the endothelial cells is neuroprotective 
because NO production acts relaxing the adjacent smooth muscle cells leading to vasodilation 
and increase of blood flow in the affected cerebral region (Bolaños et al., 1999). 
 
1.11.4 Stress signaling in response to cerebral ischemia 
Among the pathophysiological events that occur after cerebral ischemia, noteworthy is the 
activation of mitogen-activated protein kinase (MAPK) cascade (Takagi et al., 2000).  MAPKs 
comprise three subfamilies: the extracellular-signal regulated protein kinases (ERK), c-jun N-
terminal kinases (JNK) and p38 (Koistinaho et al., 2002) which are signal transduction 
pathways that serve several different functions at the cellular level. In particular, following focal 
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cerebral ischemia in the rat, activation of both ERK and p38 MAPK up to 24 after ischemia 
was reported (Irving et al., 2000 a). 
Most evidence indicates that ERK activation is associated with the regulation of cell 
proliferation and differentiation (Tibbles et al., 1999) and exerts neuroprotection mediated by 
neurotrophins and in particular by the brain-derived neurotrophic factor (BDNF) (Han et al., 
2000). Differently, JNK and p38 MAPK activation is involved in responses to environmental 
stress, cell suffering and death (Xia et al., 1995; Kummer et al., 1997; Takeda et al., 2002) and 
plays a role in neuronal damage and angiogenic response in cerebral ischemia (Lennmyr et al., 
2002). Concerning p38 MAPK, data agree on protection by p38 inhibition against focal 
ischemia induced infarct, neurological deficit and expression of inflammatory cytokines 
(Barone et al., 1999, 2001 a). Several studies have shown that all MAPKs are activated twenty-
four hours after focal brain ischemia in the rat (Irving et al., 2000 a): p38 and ERK in neurons 
and in microglia (Irving et al., 2000 a; Takagi et al., 2000; Piao et al., 2003; Melani et al., 2009), 
JNK in neurons and in oligodendrocytes (Melani et al., 2009). 
 
1.11.5 Neuroinflammation 
A few hours after the ischemia onset a switch from the ischemic damage to the inflammatory 
damage occurs. The inflammatory response is characterized by the activation of microglia and 
the influx of peripheral leukocytes (neutrophils, lymphocytes and monocytes) in the brain 
parenchyma that promotes  alteration of the blood brain barrier (BBB) permeability (Iadecola 
et al., 2011). 
Microglial cells are the resident macrophages of the brain and play a critical role as resident 
immunocompetent and phagocytic cells in the CNS. Ekdahl and colleagues (Ekdahl et al., 2009) 
reported an increased number of activated microglial cells up to 16 weeks after two hours 
middle cerebral artery occlusion (MCAO) in rats. After activation by ischemia, microglia can 
transform into phagocytes that can release a variety of substances many of which are cytotoxic. 
There is substantial evidence that activated microglial cells in response to ischemia have the 
potential of releasing several pro-inflammatory cytokines such as tumor necrosis factor-α 
(TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), as well as other potential cytotoxic 
molecules including NO, ROS and prostanoids (Lucas et al., 2006). Other cytokines related to 
inflammation in acute stroke are interleukin-10 (IL-10) and transforming growth factor (TGF)- 
β. While IL-1β and TNF-α, appear to exacerbate cerebral injury, TGF- β and IL-10 may be 
neuroprotective (Spera et al., 1998; Zhu et al., 2002). Increased production of proinflammatory 
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and lower levels of the anti-inflammatory IL-10 are related to larger infarctions and poorer 
clinical outcome.  
Astrocytes are known for their ability to express different kinds of inflammatory mediators such 
as cytokines, chemokines, and the inducible NOS (iNOS) (Dong et al., 2001) Following 
ischemia astrocytes become activated, they increase the expression of the glial fibrillary acidic 
protein (GFAP) and participate to the cerebral inflammation by expressing the major 
histocompatibility complex (MHC) and by stimulating the expression of cytokines such as IL-
2 (Dong et al., 2001). 
There is increasing evidence that cellular adhesion molecules (CAMs) play an important role 
in the pathophysiology of acute ischemic stroke (Yilmaz et al., 2008). CAMs are upregulated 
after stroke and are responsible for the adhesion and migration of the leukocytes. Leukocytes 
roll on the endothelial surface and then adhere to the endothelial cells. The interaction between 
leukocytes and the vascular endothelium is mediated by three main groups of CAMs: the 
selectins, the intracellular adhesion, (ICAM-1,2) and vascular cell adhesion (VCAM-1) 
molecules and the integrins. Selectins, especially E- and P-selectin are upregulated and 
mediated leukocytes rolling and recruitment during the early stages of ischemia (Zhang et al., 
1998). It has been shown that the blockade of adhesion molecules leads to a reduction of 
neurological damage (Clark et al., 1995, 1997). 
Neutrophils are the first leukocyte subpopulation to be recruited into the ischemic brain and 
may exacerbate the damage following the release of deleterious substances or of inflammatory 
mediators (Hallenbeck, 1996). Therefore, the inhibition of neutrophil infiltration can 
significantly reduce the infarct volume after ischemia (Bowes et al., 1995; Clark et al., 1995; 
Chopp et al., 1996; Connolly et al., 1996; Yenari et al., 1998; Garau et al., 2005). Following 
permanent middle cerebral artery occlusion (MCAo) in rats, lymphocytes represent the second 
most abundant leukocyte subtype, after neutrophils, infiltrated in the ischemic lesion (Stevens 
et al., 2002) and exert pro-inflammatory actions, harmful for the cerebral tissue (Nadareishvili 
et al., 2004). 
Other molecules upregulated in the brain in response to injury are the matrix metalloproteinases 
(MMPs) (Montaner et al., 2001).  
MMPs are a family of proteolytic enzymes that are responsible for remodeling the extracellular 
matrix and that can degrade all its constituents. Neurons, astrocytes, microglia, and endothelial 
cells have all been shown to express MMPs after injury. Stroke is associated with the disruption 
of the BBB leading to edema and hemorrhage and experimental studies have shown that these 
events results from the expression and activation of MMPs (Asahi et al., 2001). Among the 
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MMPs, the MMP-2 and MMP-9 are implicated in cerebral ischemia. Elevated MMP-9 levels 
were found in brain tissue and in serum from patients with acute ischemic stroke and in animal 
models of stroke beginning at 12 hours after permanent MCAo (Lakhan et al., 2013). 
The described post-ischemic neuroinflammatory changes are summarized in Figure 18.  
 
 
Figure 18. Post-ischemic inflammatory response. Excitotoxicity and oxidative stress caused by the 
initial ischemic event activate microglia and astrocytes which react by secreting cytokines, chemokines 
and matrix metalloproteases (MMP). These inflammatory mediators lead to an upregulation of cell 
adhesion molecules on endothelial cells, allowing blood derived inflammatory cells, mainly neutrophils, 
to infiltrate the ischemic brain area. Neutrophils themselves also secrete cytokines which cause a further 
activation of glial cells. These processes all result in neuronal cell death and enhance the damage to the 
ischemic brain. From Lakhan et al., 2009 
 
1.11.6 Cellular death 
After cerebral ischemia, brain cells that are compromised by excessive glutamate-receptor 
activation, Ca2+ overload, oxygen radicals or by mitochondrial and DNA damage can die by 
necrosis or apoptosis. Necrosis is the predominant mechanism that follow acute, permanent, 
vascular occlusion, whereas in milder injury, the predominant mechanism is the apoptosis, 
particularly within the ischemic penumbra. Some of the major morphological changes that 
occur with necrosis include: cell swelling, formation of cytoplasmic vacuoles, distended 
endoplasmic reticulum, formation of cytoplasmic blebs, condensed, swollen or ruptured 
mitochondria, disaggregation and detachment of ribosomes, disrupted organelle membranes, 
swollen and ruptured lysosomes, and eventually disruption of the cell membrane (Trump et al., 
n.d.; Kerr et al., 1972; Majno et al., 1995). This loss of cell membrane integrity results in the 
release of the cytoplasmic contents into the surrounding tissue, sending chemotactic signals 
with eventual recruitment of inflammatory cells (Elmore, 2007). 
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Apoptosis (or controlled cell death) is induced by many signals. The enzymes involved in 
apoptosis are the caspases, whose gene is highly expressed during the infarction (Dirnagl et al., 
1999). To date, research indicates that there are two main apoptotic pathways: the extrinsic or 
death receptor pathway and the intrinsic or mitochondrial pathway (Figure 19).  
Post-ischemic apoptosis occurs via intrinsic (or mitochondrial) activation: caspases become 
activated when cytochrome C, released from mitochondria, leading to the activation of caspase-
9. Caspase-9 activates, among others, the caspase-3 which initiates the cell death by apoptosis 
(Carbonell et al., 2007). 
 
Figure 19. Schematic representation of the two main pathways of apoptosis: extrinsic and intrinsic. 
Each requires specific triggering signals to begin an energy-dependent cascade of molecular events. 
Each pathway activates its own initiator caspase (8, 9) which in turn will activate the executioner 
caspase-3. The execution pathway results in characteristic cytomorphological features including ce ll 
shrinkage, chromatin condensation, formation of cytoplasmic blebs and apoptotic bodies and finally 
phagocytosis of the apoptotic bodies by adjacent parenchymal cells, neoplastic cells or macrophages. 
Modified from (Elmore, 2007). 
 
1.12 Adenosine in cerebral ischemia 
The increase of extracellular adenosine concentration during in vivo ischemia (Dux et al., 1990; 
Hagberg et al., 1987; Matsumoto et al., 1992; Melani et al., 1999; Phillis et al., 1994, 1996; 
Sciotti et al., 1992) is attributable to different reasons. Early after ischemia, the increase of 
adenosine is mainly due to extracellular released ATP (Melani et al., 2012) that is hydrolysed 
by ectonucleotidases (NTPDases 1, 2 and 3 that convert ATP o ADP and AMP) and ecto-5’-
nucleotidase that converts AMP to adenosine (Zimmermann, 2000; Fausther et al., 2012). 
Thereafter adenosine per se is mainly released from cells likely by the ENT2 (Melani et al., 
2012). Inhibition of adenosine-uptake processes due to down-regulation of CNT2 and 3 and of 
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the ENT1 also contributes to the extracellular adenosine increase after stroke (Medina-Pulido 
et al., 2013). 
The extracellular adenosine concentrations reached after ischemia allow the stimulation of all 
four adenosine receptor subtypes (A1, A2A, A2B and A3). In particular, their wide distribution 
on neuronal, glial and inflammatory cells (Fiebich et al., 1996; Brodie et al., 1998; 
Svenningsson et al., 1999; Hettinger et al., 2001; Yu et al., 2004), suggests that the role of 
adenosine in ischemia is the consequence of an interplay among different receptor activation, 
which changes depending on the time-related development of the pathological condition 
(Pedata et al., 2014). 
During ischemia, adenosine has long been identified as a neuroprotectant endogenous agent 
(Cunha, 2001; Pedata et al., 2007; Fredholm et al., 2003; Ongini et al., 1997; Ribeiro et al., 
2002; Schwarzschild et al., 2002).  It was demonstrated that adenosine infusion into the 
ischemic striatum significantly ameliorated neurological outcome and reduced infarct volume 
after transient focal cerebral ischemia (Kitagawa et al., 2002). All these protective effects are 
greatly attributed to A1 receptor activation due to reduced Ca2+ influx, thus lowering presynaptic 
release of excitatory neurotransmitters (Andiné, 1993; Corradetti et al., 1984; Dunwiddie, 1984; 
Zetterström et al., 1990; Pedata et al., 1993; Kitagawa et al., 2002) and in particular of glutamate 
which exerts an excitotoxic effect during ischemia mainly by overstimulation of NMDA 
receptors (Choi, 1990). In addition, by directly increasing the K+ and Cl- ion conductances, 
adenosine stabilises the neuronal membrane potentials, thus reducing neuronal excitability 
(Choi, 1990). Nevertheless, the use of selective A1 agonists is hampered by undesirable effects 
such as sedation, bradycardia, hypotension (White et al., 1996; Fredholm et al., 2005).  
Beyond the protective effects of A1 receptor, important roles in cerebral ischemia of the other 
receptor subtypes have been outlined in the last years. It has been demonstrated that both 
antagonist and agonist of adenosine A2A receptor exert protective effects attributable to different 
mechanism. The neuroprotective properties of adenosine A2A receptor antagonists largely 
reside in effects mediated by A2A receptors located on brain cells, in particular in control of 
excitotoxicity as demonstrated by the observation that the A2A receptor selective antagonist, 
ZM241385, injected peripherally or directly intra hippocampus is protective against 
excitotoxicity induced by kainate (Jones et al., 1998) and by the combinations of quinolinic 
acid and IL-1β (Stone et al., 2007). Moreover, A2A receptor antagonists protect from ischemia–
induced activation of Mitogen-Activated Protein Kinases (MAPKs) expression.  Twenty-four 
hours after focal ischemia, a definite over expression of A2A receptors (Trincavelli et al., 2008) 
and an activation of p38 and ERK1/2 MAPKs was found in neurons and in microglia of the 
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ischemic tissue (Irving et al., 2000 b; Takagi et al., 2000; Piao et al., 2003; Melani et al., 2006 
a). Sub-chronic administration of the A2A receptor antagonist, SCH58261, has reduced 
phospho-p38 in microglia while it did not affect ERK1/2 MAPK activation 24 hours after 
ischemia (Melani et al., 2006 a). A control of p38 activation by A2A receptor antagonism 
(Melani et al., 2006 ) might account for neuroprotection after ischemia as demonstrated in brain 
slices after OGD (Barone et al., 2001 b).  
Apparently in a paradoxical manner, also A2A agonists exert protective effect. Activation of 
central A2A receptors is known to increase expression and release of neurotrophic factors 
(Sebastião et al., 1996) such as nerve growth factor (NGF) in microglia (Heese et al., 1997), 
BDNF in mice hippocampus (Tebano et al., 2008), in rat cortical neurons (Jeon et al., 2011) 
and in primary cultures of microglia (Gomes et al., 2013); glial cell line-derived neurotrophic 
factor (GDNF) in striatal neurons (Gomes et al., 2006). The increase in neurotrophic factor 
expression by adenosine A2A receptor stimulation may contribute to restore neurological 
functions and cerebral damage after brain ischemia. Besides protective effect attributable to 
A2A expressed at central level, a bulk of evidences indicate that peripheral effects on A2A  
receptors located on blood cells greatly account for protective effects of adenosine A2A agonists 
after ischemia. Adenosine A2A receptors are present, in fact, on peripheral blood marrow 
derived cells including platelets, monocytes, mast cells, neutrophils and T cells where selective 
activation of A2A receptors reduces production of adhesion cell factors, reduces platelet 
aggregation and neutrophil activation exerting therefore an antiplatelet, antioxidant and anti -
inflammatory effect. (Haskò et al., 2000; Lappas et al., 2006; Sitkovsky et al., 2004; Varani et 
al., 1998). 
In particular, it has been demonstrated that A2A receptor activation reduced ischemia-induced 
rolling, adhesion and transmigration of various peripheral inflammatory cells (such as 
lymphocytes, neutrophils) (Haskó et al., 2008). In agreement, A2A agonists, systemically 
administered, protected from inflammation in various models of autoimmune disease such as 
rheumatoid arthritis (Szabó et al., 1998; Mazzon et al., 2011), colitis (Odashima et al., 2005; Di 
Paola et al., 2010), and hepatitis (Choukèr et al., 2008) and in models of spinal cord trauma (Li 
et al., 2006; Genovese et al., 2009; Paterniti et al., 2011) and of traumatic brain injury (Dai et 
al., 2010). 
The few studies present in the literature concerning the role of adenosine A3 receptor in cerebral 
ischemia are rather contradictory (Borea et al., 2009; Pedata et al., 2010). The effects of 
adenosine A3 receptor stimulation appear to depend on drug administration (acute vs chronic), 
dosage and timing of treatment with respect to the onset of the ischemic insult. 
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1.12.1 Adenosine A2B receptor in cerebral ischemia 
Adenosine A2B receptor is expressed at low levels uniformly throughout the CNS (Puffinbarger 
et al., 1995; Dixon et al., 1996; Fredholm et al., 2000) and has a low affinity for adenosine. 
Their mRNA and protein expression levels increase on endothelial cells, neurons, and 
astrocytes to a greater extent than do those of the other three adenosine receptors (A1, A2A, and 
A3) 24 hours after tMCAo in the rat (Li et al., 2017). Thus, during conditions of hypoxia or 
ischemia when the extracellular adenosine levels rise, A2B receptors might be well activated 
(Xu et al., 2013). Because of paucity of A2B selective agonists and antagonists (Müller et al., 
2011) few studies are till now present on the role of A2B receptors in brain ischemia. 
Recently, the role of A2B receptor selective antagonists was investigated under OGD. Fusco et 
al., (2018) demonstrated that, in the CA1 area of the rat hippocampus, the selective A2B receptor 
antagonists, N-(4-Cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-
yl) phenoxy]–acetamide (MRS1754) and 8-[4-[4-(4-Chlorophenzyl) piperazide-1-sulfonyl) 
phenyl]] -1-propylxanthine) (PSB603) prevented the appearance of AD, a phenomenon strictly 
related to cell damage and death (Pugliese et al., 2006) and protected from the synaptic activity 
depression, bringing to a significant recovery of an otherwise disrupted neurotransmission 
induced by 7 min OGD (Fusco et al., 2018). Adenosine A2B receptor antagonism also 
counteracted the reduction of neuronal density in CA1 stratum pyramidale, decreased apoptosis 
at least up to 3 hours after the end of OGD and prevented astrocyte modification (Fusco et al., 
2018).  
The selective A2B antagonist, N-(4-acetylphenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-
dipropyl-1H-purin-8-yl) henoxy] acetamide (MRS1706), completely prevented in human 
astroglial cells elongation of astrocytic processes (a morphological hallmark of in vivo reactive 
astrogliosis) induced by selective stimulation of A2B receptors (Trincavelli et al., 2004). 
Moreover, a short-term TNF-α treatment induced A2B adenosine receptor desensitization in 
human astroglial cells (Trincavelli et al., 2004). These results suggest that in the acute phase of 
brain ischemia characterized by both cytokine and adenosine high release, A2B receptor 
desensitization on astroglia might represent a cell defense mechanism (Trincavelli et al., 2004). 
Few studies have investigated the role of A2B receptors in brain ischemia in vivo. It was reported 
that the selective A2B receptor antagonist, MRS1754, reduced the ceramide production in 
astrocytes and attenuated inflammatory responses and neuronal damage after 30 minutes and 6 
hours in a model of global cerebral ischemia induced by four-vessel occlusion in the rat (Gu et 
al., 2013). This effect was related to an early reduction of p38 MAPK activation. In fact, A2B 
receptor plays a key role in the rapid activation of p38 and in the subsequent inflammatory 
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process (Koscsó et al., 2012; Wei et al., 2013). Altogether experiments indicated that 
antagonism of A2B receptor located on brain cells might be protective from ischemic brain 
damage. 
Besides brain cells, A2B receptors are present on blood immune cells i.e neutrophils, 
lymphocytes (Gessi et al., 2005; Eckle et al., 2008) where in most cases they are co-expressed 
with A2A receptors. They are also expressed at low levels on platelets, where they are 
upregulated following injury and systemic inflammation in vivo inducing an inhibition of 
platelet aggregation (Yang et al., 2010). Moreover, A2B receptors are expressed on the surface 
of endothelial cells (Feoktistov et al., 2004) where they are up regulated by the hypoxia 
inducible factor (HIF-1α) (Eltzschig et al., 2004). In agreement, vascular permeability was 
significantly increased in organs of A2B receptor KO mice subjected to ambient hypoxia. By 
contrast, hypoxia-induced vascular leak was not accentuated in A1, A2A or A3 receptor KO mice, 
suggesting a specific role of A2B receptor in endothelial cells (Eckle et al., 2007). Moreover, 
A2B receptor KO mice exposed to hypoxia exhibit increased neutrophil infiltration into hypoxic 
tissues revealing an inhibitory role for A2B receptors in neutrophil transmigration in vivo (Eckle 
et al., 2007, 2008). Attenuation of hypoxia-associated increases in tissue neutrophil numbers 
appeared to depend largely on hematopoietic cell A2B receptor signaling (Yang et al., 2006; 
Eckle et al., 2007). 
Recent introduction of new pharmacological tools (Hinz et al., 2014) led to understand a role 
of A2B receptor in ischemia. Intravenous treatment with the selective A2B receptor agonist 
BAY60-6583 (1 mg/kg), at the start of reperfusion after brain ischemia induced by tMCAo, 
reduced lesion volume and attenuated brain swelling and BBB disruption. In the presence of 
tPA (administered after ischemic stroke to dissolve intravascular clots), BAY60-6583 also 
mitigated sensorimotor deficits and reduced tPA induced hemorrhages at 24 hours after 
ischemia (Li et al., 2017). The neurovascular protection afforded by BAY60-6583 appears to 
derive from stimulation of the tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) 
production, inhibition of tPA-induced matrix metalloprotease (MMP) activation, and 
prevention of tight junction protein degradation. In fact, over-activation of MMP leads to 
increased cerebrovascular permeability after ischemia-reperfusion injury (Mishiro et al., 2012). 
Thus, this study proposed that A2B receptor agonists might be adjuvant to tPA and could be a 
promising strategy for decreasing the risk of hemorrhages during treatment for ischemic stroke  
(Li et al., 2017).  
All together these studies point toward a role of central A2B receptors, in synergy with A2A  
receptors in promoting brain excitotoxicity, while A2B receptors located on vascular endothelial 
________________________________________________________________________________ Introduction 
47 
 
cells would play a pivotal role in attenuating hypoxia-induced increases in vascular leak. Blood 
immune cells would be implicated in dampening vascular adhesion signals and hypoxia-
induced inflammation (Koeppen et al., 2011). 
To date there are no evidences in literature on the protective effects of A2B receptor agonists at 
more distant times from ischemia when a defined neuroinflammation develops.  
 
Role of Carbonic Anhydrase Inhibitors in cerebral ischemia 
 
The Carbonic anhydrases (CAs; also known as carbonate dehydratases) are a superfamily of 
metalloenzymes present in prokaryotes and eukaryotes that are encoded by five distinct, 
evolutionarily unrelated gene families: 
- α-CAs: present in vertebrates, plants and algae 
- β-CAs: present in bacteria, algae and fungi; 
- γ-CAs: present in archaea and bacteria; 
- δ-CAs and ζ-CAs: both present in marine diatoms. 
 
Of the five different classes of CA, the α class has perhaps received the most attention because 
of its role in human pathology. Indeed, a large number of α-CA isoforms have been described 
in vertebrates: 15 in humans and other primates, and 16 in other mammals, with different 
catalytic activity, subcellular localization and tissue distribution. There are five cytosolic forms 
(CA I, CA II, CA III, CA VII and CA XIII), five membrane-bound enzymes (CA IV, CA IX, 
CA XII, CA XIV and CA XV), two mitochondrial forms CA (Va and CA Vb), and a secreted 
CA isozymes (CA VI).  Three a-catalytic forms are also known, which are denominated CA 
related proteins (CARP), CARP VIII, CARP X, and CARP XI. 
 
1.13 CA Structure and Mechanism  
CA catalyze a simple physiological reaction: the conversion between carbon 
dioxide and water and the dissociated ions of carbonic acid (i.e. bicarbonate and hydrogen 
ions) (Figure 20) and are thus involved in crucial physiological processes connected with 
respiration and transport of CO2/bicarbonate between metabolizing tissues and lungs, pH and 
CO2 homeostasis, electrolyte secretion in a variety of tissues/organs, biosynthetic reactions 
(such as gluconeogenesis, lipogenesis and ureagenesis), bone resorption, calcification, 
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tumorigenicity, and many other physiologic or pathologic processes (Hewett-Emmett, 2000; 
Supuran et al., 2000, 2002). 
 
Figure 20. Reaction catalyzed by CA. 
 
The basic catalytic mechanism of CA was established from studies of bovine CA and human 
CAs I and II  (Silverman et al., 1983, 1988).  
The active site of CAs contains a zinc ion (Zn2+), which is essential for catalysis. X-ray 
crystallographic data show that the ion is situated at the bottom of a 15 Å deep active-site cleft, 
and is coordinated by three histidine residues (His94, His96 and His119) and a water 
molecule/hydroxide ion (Supuran, 2008) (Figure 21). 
 
Figure 21. Cartoon structure of CA II; His residues coordinating the catalytic zinc are shown as sticks 
and labeled. The zinc-bound hydroxide ion/water is represented as a red sphere. Modified from 
(Lomelino et al., 2016). 
 
The zinc-bound water is also engaged in hydrogen bond interactions with the hydroxyl moiety 
of Thr 199, which in turn is bridged to the carboxylate moiety of Glu 106; these interactions 
enhance the nucleophilicity of the zinc-bound water molecule and orient the substrate (CO2) in 
a favorable location for the nucleophilic attack (Figure 22). 
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Figure 22. Schematic representation of the catalytic mechanism for the CA. From (Supuran, 2003). 
 
The active form of the enzyme is the basic one, with hydroxide bound to Zn2+ (Figure 22 A). 
This strong nucleophile attacks the CO2 molecule that is bound in hydrophobic pocket in its 
neighborhood (Figure 22 B), leading to the formation of bicarbonate coordinated to Zn2+ 
(Figure 22 C). The bicarbonate ion is then displaced by a water molecule and liberated into 
solution, leading to the acid form of the enzyme, with water coordinated to Zn2+ (Figure 22 D), 
which is catalytically inactive (Supuran, 2008). 
 
1.14 CA Inhibition  
Two main classes of carbonic anhydrase inhibitors (CAIs) are known: the metal-complexing 
anions (thiocyanate, azide etc.) and the unsubstituted sulphonamides and their biososteres. 
These inhibitors act by binding to the catalytic Zn2+ ion in the active site of the enzyme and 
blocking its function (Neri et al., 2011). 
There are over 20 CAIs that have received FDA approval or are in clinical trials for drug 
therapies (Mincione et al., 2007; Pinard et al., 2013). However, the majority of these compounds 
are sulfonamide-based and act systemically.  
The sulfonamides were recognized to act as potent CAIs already in the 1950, and the first 
diuretic based on this class of pharmacologic agents, acetazolamide (5-acetamido-1,3,4-
thiadiazole-2-sulfonamide), started to be clinically used in 1956, with this drug still being used 
nowadays (Supuran, 2008). 
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The CAIs are clinically used  as diuretics (Carta et al., 2013), anti-epileptics agents (Thiry et 
al., 2007; Aggarwal et al., 2013), anti-glaucoma drugs (Carta et al., 2012; Masini et al., 2013 
a), and were recently validated for management of neuropathic pain (Carta et al., 2015; Supuran, 
2016), cerebral ischemia (Di Cesare Mannelli et al., 2016) and rheumatoid arthritis (Margheri 
et al., 2016; Bua et al., 2017). A crucial problem in CAIs design is related to the high number 
of isoforms, their diffuse localization in many tissue and organs (see Table 3) and the lack of 
isozyme selectivity of the presently available inhibitors. 
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Isozymes Subcellular Localization Tissue/Organ 
Localization 
CA I Cytosol Erythrocytes, GI tract 
CA II Cytosol Erythrocites, eye, GI tract, 
bone osteoclasts, kidney, lung, 
testis, brain 
CA III Cytosol Skeletal muscle, adipocytes 
CA IV Membrane-bound Kidney, lung, pancreas, brain, 
capillaries, colon, heart muscle 
CA Va Mitochondria liver 
CA Vb Mitochondria Heart and skeletal muscle, 
pancreas, kidney, spinal cord, 
GI tract 
CA VI Secreted (saliva, milk) Salivary and mammary glands 
CA VII Cytosol CNS 
CA VIII Cytosol CNS 
CA IX Transmembrane Tumours, GI mucosa 
CA X Cytosol CNS 
CA XI Cytosol CNS 
CA XII Transmembrane Renal, intestinal, reproductive 
epithelia, eye, tumours 
CA XIII Cytosol Kidney, brain, lung, gut, 
reproductive tract 
CA XIV Transmembrane Kidney, brain, liver 
CA XV Membrane-bound Kidney 
Table 3. CA distribution. GI= gastro-intestinal. Modified from (Supuran, 2008). 
 
1.15 Role of CAIs in the CNS  
The human CNS as well as the choroid plexus are among the tissues/organs having the highest 
number of CA isoforms, although their functions are still not completely understood.  
Given the multitude of CA isoforms in the CNS, their inhibition was exploited therapeutically 
for anticonvulsant agents already in the ‘70s, with acetazolamide and methazolamide the most 
used agents, in some forms of epilepsy (Aggarwal et al., 2013). The mechanisms by which 
CAIs show antiepileptic action are rather complex and there is not a definitive consensus among 
researchers on many aspects related to this pharmacological effect (Aggarwal et al., 2013; 
________________________________________________________________________________ Introduction 
52 
 
Hamidi et al., 2015). Inhibition of brain CAs leads to a diminished formation of bicarbonate 
and also changes the brain pH, contributing thus to an antiepileptic effect by several diverse 
pathways, among which the diminished depolarization of principal cells and of interneurons 
being the crucial factors (Aggarwal et al., 2013; Hamidi et al., 2015). Sulfonamides are scarcely 
used clinically as antiepileptic drugs, due to their promiscuous inhibition of most CA isoforms 
and as a consequence a multitude of side effects (Supuran, 2008). More recent, drugs such as 
topiramate and zonisamide are widely clinically used such agents in many types of epilepsy 
(Thiry et al., 2007; Aggarwal et al., 2013). 
There are several other possible pharmacologic applications of the CAIs related to the inhibition 
of CNS isoforms, including neuropathic pain (Carta et al., 2015; Supuran, 2016) and cerebral 
ischemia (Di Cesare Mannelli et al., 2016). Neuropathic pain affects up to 8% of the population 
with few therapeutic options available for its management (Supuran, 2016). Recent advances 
in understanding the pathological mechanisms of this syndrome and the 
biochemical/pharmacological characterization of novel drug targets, evidenced that CA 
inhibition might be a novel approach for obtaining anti-neuropathic pain agents (Carta et al., 
2015; Supuran, 2016). Novel classes of selective sulfonamide CAII/VII inhibitors were 
designed (Carta et al., 2015), which indeed showed highly improved efficacy in animal model 
of neuropathic pain, compared to acetazolamide, offering the basis for the development of 
specific therapies based on selective CA isoforms inhibition. 
 
1.15.1 Role of CAIs in cerebral ischemia 
Recently a relationship between hypoxia, a key feature of cerebral ischemia, and several CA 
isoforms over-expression through the hypoxia-inducible factor (HIF) transcription factor has 
been highlighted (Neri et al., 2011), suggesting CA IX/XII inhibition as a possible target for 
this condition (Di Cesare Mannelli et al., 2016; Supuran et al., 2018).  
Few studies are present in literature about carbonic anhydrase and its inhibitors in cerebral 
ischemia. Among them, Regli et al. (Regli et al., 1971) demonstrated that cats underwent middle 
cerebral artery occlusion and treated with acetazolamide (500 mg via intramuscularly), 
appeared to have more severe neurological deficits, larger areas of ischemia and infarction and 
more brain swelling respect to untreated cats. 
A recent study (Di Cesare Mannelli et al., 2016) evaluated the pharmacological profile of 
several coumarin 23 and sulfonamide 24 CAIs in an animal model of cerebral ischemia, rats 
which underwent a permanent middle cerebral artery occlusion (pMCAO). Vehicle-treated rats 
showed a clear neurological deficit after pMCAo, and repeated subcutaneous injections, 5 and 
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20 minutes after pMCAo, of the CAIs 23 and 24 (at 1 mg/kg subcutaneously) were able to 
significantly reduce the neurological deficit. Sulfonamide 24 also showed the tendency to 
reduce the infarct volume after pMCAo (Di Cesare Mannelli et al., 2016), whereas the classic 
CAI, acetazolamide,  was ineffective neither to reduce neurological deficit nor to reduce brain 
damage. The properties of novel CAIs to improve neurological functionalities after cerebral 
ischemic insult were thus for the first time demonstrated, opening the way to a novel, innovative 
pharmacological treatment of this condition. 
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Aim of Section I: 
Role of adenosine A2B receptor on differentiation in cultured 
oligodendrocyte precursor cell and possible interaction with 
SphK/S1P signaling pathway. 
Oligodendrocyte progenitor cells (OPCs) are a population of cycling cells which persist in the 
adult central nervous system (CNS) where, under opportune stimuli, differentiate into mature 
myelinating oligodendrocytes. While the role of adenosine A1 and A2A receptors during OPCs 
development was investigated, the role of A2B and A3 receptors is still unclear. 
The bioactive lipid mediator S1P has recently gained attention in myelination within the CNS  
since its receptors (S1P1-5) are found in oligodendroglial cells, where they regulate a number of 
processes, ranging from cell proliferation and maturation to dendrite elongation.  
From these evidences, it appears that both adenosine receptors and SphK/S1P signaling are key 
regulators of oligodendrocyte development.  
The aim of the present study was to investigate the still unknown functional role of adenosine 
A2B receptors and its possible interaction with SphK/S1P signaling pathway in OPC maturation.  
We thus investigated the effects of adenosine A2B receptor ligands and SphK/S1P modulators 
on myelin basic protein (Mbp) and myelin-associated glycoprotein (MAG) expression at 
different times in culture. 
 
Aim of Section II: 
Role of adenosine A2B receptor agonist, BAY60-6583, in a transient 
model of focal cerebral ischemia in the rat. 
Adenosine A2B receptors are expressed at low levels uniformly throughout the CNS and has a 
low affinity for adenosine. An overexpression of A2B receptors occurs on endothelial cells, 
neurons, and astrocytes 24 hours after tMCAo in the rat. Thus, during conditions of hypoxia or 
ischemia when the extracellular adenosine levels rise, A2B receptors might be well activated in 
the CNS. Besides brain cells, A2B receptors are present on blood immune cells i.e neutrophils, 
lymphocytes that take part in the inflammatory phenomena that developing hours and days after 
ischemia, contribute to enlarge the ischemic damage. Thus, A2B receptors might play a crucial 
role in the inflammatory phenomena.  
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To date there are no evidences in literature on the effects of A2B receptor ligands after ischemia 
when a defined neuroinflammation develops. Purpose of the present work was to check the 
putative neuroprotective effects of the adenosine A2B agonist, BAY60-6583 chronically 
administered for 7 days after transient (1 hour) focal cerebral ischemia induced by MCAo in 
the rat. 
 
Aim of Section III: 
Role of carbonic anhydrase inhibitors in a rat model of cerebral 
ischemia  
The evidence that hypoxic microenvironments elicit the expression of specific isoform of CA 
(in particular CA IX and CA XII) through the hypoxia inducible factor allows to hypothesize a 
possible relevant role of CA in ischemia. 
Recently it has been demonstrated that carbonic anhydrase inhibitors (CAIs), sulfonamide and 
coumarin, were able to improve neurological functionalities after cerebral ischemic insult.  
Preliminary data obtained in our laboratory in a model of in vitro ischemia (data not yet 
published) demonstrated that two CAIs, acetazolamide and AN11-740 were able to prevent the 
appearance of anoxic depolarization (AD), a phenomenon strictly related to cell damage and 
death, 30 minutes after oxygen and glucose deprivation (OGD) condition in hippocampal slices. 
Based on this preliminary result, the aim of this study was to investigate the putative protective 
effect of two CAIs, acetazolamide and AN11-740 in the in vivo model of permanent cerebral 
ischemia in the rat.  
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Section I. 
3.1 Cell cultures 
Purified cortical OPC cultures were prepared as described elsewhere (Coppi et al., 2013 b). 
Wistar rat pups (postnatal day 1-2) were killed and cortices removed, mechanically and 
enzymatically dissociated, suspended in DMEM medium containing 20% fetal bovine serum 
(FBS), 4 mM L-glutamine, 1 mM Na-pyruvate, 100 U/ml penicillin, 100 U/ml streptomycin 
(all products are from EuroClone, Milan, Italy), and plated in poly-D-lysin coated T75 flasks 
(1 flask per animal). After 2-3 days in culture, OPCs growing on top of a confluent monolayer 
of astrocytes were detached by 5 h of horizontal shaking. Contaminating microglial cells were 
eliminated by a 1 h pre-shake and by further plating of detached cells on plastic culture dishes 
for 1 h. OPCs, which do not attach to plastic, were collected by gently washing the dishes and 
replated onto poly-DL-ornithine-coated (final concentration: 50 μg/ml, Sigma-Aldrich) 13 mm-
diameter glass coverslips laid in 24 multi well chambers (l04 cells/well: electrophysiological 
and immunocytochemical experiments), poly-DL-ornithine-coated 25 mm-diameter glass 
coverslips laid in 6 multi well chambers (2 x l04 cells/well: Ca2+ imaging experiments) or poly-
DL-ornithine-coated 6 cm tissue culture dishes (3.5 x 105 cells/dish: western-blot experiments). 
OPC cultures were maintained in Neurobasal medium (Thermo Fisher Scientific) containing 
2% B27, 4 mM L-glutamine, 1 mM Na-pyruvate, 100 U/ml penicillin, 100 U/ml streptomycin, 
10 ng/ml platelet derived growth factor (PDGF-BB) and 10 ng/ml basic fibroblast growth factor 
(bFGF; both grow factors were from PeproTech EC Ltd, London, UK) to promote cell 
proliferation (proliferating medium: PM). 
 
3.2 OPC differentiation 
OPCs show a bipolar or tripolar morphology, when grown in a proliferating medium (PM); they 
were allowed to differentiate to mature oligodendrocytes, by switching to a Neurobasal medium 
lacking growth factors (differentiating medium: DM). The day at which cells were switched 
from PM to DM is indicated as t0. According to our previous results (Coppi et al., 2013a; Coppi 
et al., 2013b), cells cultured in DM undergo gradual maturation as demonstrated by the decrease 
on NG2 expression and the parallel increase in myelin-related proteins such as MAG, Mbp1 
and Mbp3 antigens. After 7 days in DM (t7) the expression of myelin-related proteins reaches 
steady state levels (no further increase at t10 was observed) so the culture is considered to be 
composed of mature OLs. In order to study the effect of adenosine A2B receptor and/or 
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SphK/S1P signaling pathway on oligodendroglial maturation, OPCs were grown in DM in the 
absence or presence of different pharmacological treatments for 7 days (from t0 to t7). 
 
3.3 Real-time PCR 
Gene expression analysis was performed by Real-Time PCR, using 2  ^ (-ΔΔCT) comparative 
method of quantification (Livak et al. 2001). Briefly, total RNA (500 ng), extracted with 
GenElute™ Mammalian Total RNA Miniprep (Sigma-Aldrich s.r.l. Milan, Italy at 
http://www.sigma-aldrich.com) was reverse transcribed using iScript™ Advanced cDNA 
Synthesis Kit for RT-qPCR (Bio-Rad Laboratories S.r.l., Segrate (MI), Italy, at http://www.bio-
rad.com/) according to the manufacturer's instructions. The design of MAG, Mbp and A2B 
probes was performed employing Primer Express® Software v3.0.1 (Thermo Fisher Scientific 
INC. Monza (MB), Italy, at https://www.thermofisher.com/) that provides customized 
application-specific documents for absolute and relative quantitation. Rat oligonucleotide 
primers employed in gene expression studies are listed in Table 4 The quantification of target 
gene mRNA levels was performed employing PowerUp™ SYBR™ Green Master Mix (Bio-
Rad Laboratories S.r.l). Each measurement was carried out in triplicate, using the automated 
ABI Prism 7500 Sequence Detector System (Thermo Fisher Scientific, INC) as previously 
described (Donati et al., 2007), by simultaneous amplification of the target gene together with 
the housekeeping gene (beta-actin and GAPDH) in order to normalize expression data. Results 
were analysed by ABI Prism Sequence Detection Systems software, version 1.7 (Applied 
Biosystems, Foster City, CA). The 2 (^−ΔΔCT) method was applied as a comparative method 
of quantification (2) and data were normalized to beta-actin expression. 
Oligo Name Sequence 5' to 3' (include modification 
codes if applicable) 
Mag-FW TTCCGAATCTCTGGAGCACCTGATAAG 
Mag-RV TCCTCACTTGACTCGGATTTCTGCGT 
Actb-FW GAACACGGCATTGTCACCAACTGGGA 
Actb-RV GCCTGGATGGCTACGTACATGGCT 
Mbp1-FW GCCCTCTGCCTTCTCATGCCC 
Mbp1-RV CCTCGGCCCCCCAGCTAAATCT 
ADORA2B-FW GTGGGAGCCTCGAGTGCTTTACAG 
ADORA2B-RV GCCAAGAGGCTAAAGATGGAGCTCTG 
Table 4. Sequences of rat oligonucleotide primers employed in gene expression studies. 
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3.4 Western blot analysis 
Primary rat cortical OPC culture were collected after 10 μM BAY60-6583 challenge for 10 min 
and lysed in a buffer containing 50 mM Tris, pH 7.5, 120 mM NaCl, 1mM EDTA, 6 mM EGTA, 
15 mM Na4P2O7, 20 mM NaF, 1% Nonidet and protease inhibitor cocktail for 30 min at 4°C. 
Then lysates were centrifuged at 10.000xg, 15 min 4°C, supernatant collected for protein 
quantification and 15 μg of protein from total cell lysates were used to perform a SDS-
polyacrylamide gel electrophoresis and Western blot (WB) analysis. The rate of 
phosphorylation of SphK1 and SphK2 was measured using the Sphingosine kinase activation 
antibody sampler kit (ECM Biosiences ECM Biosciences, Versailles, KY USA at 
https://www.ecmbiosciences.com/index.php?content=Contact. PDVF membranes were 
incubated overnight with the primary antibodies at 4°C and then with specific secondary 
antibodies for 1 h at room temperature. Binding of the antibodies with the specific proteins has 
been detected by chemiluminescence, employing Amersham imager 600. 
 
3.5 Adenosine A2B receptor silencing by RNA interference 
OPC grown into tissue culture 6-well plates up to 60% confluence, were transfected with siRNA 
duplexes using Lipofectamine RNAiMAX (Thermo Fisher Scientific INC), according to the 
manufacturer's instructions as previously described (Bruno et al 2018). Briefly, Lipofectamine 
RNAiMAX was incubated with siRNA in Neurobasal without supplement and antibiotics for 
20 minutes, and afterward the lipid/RNA complexes was added to cells to a final concentration 
of 50 nM in Neurobasal containing growth factors and supplements and without antibiotics. 
After 24 hours, OPC was shifted to differentiating medium and then used for the experiments 
within 72 hours. Successful siRNA repression was confirmed by real-time reverse transcription 
polymerase chain reaction (RT-PCR). 
 
3.6 Drugs 
2-[[6-Amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]-2-pyridinyl]thio]-acetamide 
(BAY60-6583, Figure 23); amidine analogues that inhibits sphingosine kinase, VPC96047 and 
VPC96091 (Figures 24 and 25), were kindly provided by Prof. K. Lynch (University of 
Virginia); (2S)-amino-2-[2-(4-octylphenyl)ethyl]-1-(dihydrogen phosphate)-1,3-propanediol.  
(FTY720 (S)-Phosphate, Figure 26) was provided by Cayman Chemical, (Michigan 
USAhttps://www.caymanchem.com/); the new, highly selective, adenosine A2B receptor 
agonist, (2-{[(1H-imidazol-2-yl) methyl] thio}-6-amino-4-[4-(cyclopropylmethoxy) 
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phenyl]pyridine-3,5-dicarbonitrile), P453 showed in Figure 27 (Betti et al., 2018). 5-[4-Phenyl-
5-(trifluoromethyl) thiophen-2-yl]-3-[3-(trifluoromethyl) phenyl]1,2,4-oxadiazole (SEW2871, 
Figure 28) and [3R-amino-4-[(3-hexylphenyl) amino]-4-oxobutyl]-phosphonic acid (W146, 
Figure 29) were kindly provided by Prof. F. Cencetti (University of Florence). 
 
3.7 Chemical structure of drugs 
 
Figure 23. BAY60-6583: adenosine A2B receptor agonist. 
 
 
Figure 24. VPC96047: a-specific inhibitor of the two isoforms SphK1 e SphK2. 
 
 
Figure 25. VPC96091: selective inhibitor of SphK1. 
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Figure 26. FTY720-P. 
 
 
Figure 27. P453: the non-adenosine like adenosine A2B receptor agonist. 
 
 
 
Figure 28. SEW2871: S1P1 agonist. 
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Figure 29. W146: potent and selective S1P1 antagonist. 
 
3.8 Statistical analysis 
Data are expressed as mean ± SEM (standard error of the mean). Student’s paired or unpaired 
t-tests or One-way ANOVA followed by Bonferroni’s post-hoc test analysis were performed, 
as appropriate, in order to determine statistical significance (set at P<0.05). Data were analyzed 
using software package Graphpad PRISM (GraphPad Software, San Diego, CA, USA). 
 
Section II and III: 
3.9 Animals 
Male Wistar rats (Envigo, Italy) weighting 270–290 g were used. Animals were housed in 
groups of three with free access to food and water and kept under standardized temperature, 
humidity and light conditions (12 h light/dark cycle) within the animal house facility of the 
University of Florence. The experimental procedures described were approved by the local 
Animal Welfare Body (AWB) of the University of Florence and authorized by the Italian 
Ministry of Health (Authorization n. 118/2016-PR). The ethical policy of the University of 
Florence complies with to the Directive 2010/63/EU of the European Parliament and to the 
Italian Regulation DL 26/2014 on the protection of animals used for scientific purposes. 
According to the law, all efforts were made to fulfill to the principle of 3Rs. 
 
3.10 Surgery 
Focal cerebral ischemia was induced by intraluminal middle cerebral artery occlusion (MCAo) 
in the right hemisphere. The animals were anesthetized with 5.0% isoflurane (Baxter 
International) and spontaneously inhaled 1.0 to 2.0% isoflurane in air by the use of a mask. 
Body core temperature was maintained at 37°C with a recirculating pad and K module and was 
monitored via an intrarectal type T thermocouple (Harvard, Kent, UK). The surgical procedure 
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to occlude the MCA consisted in insertion of a 4-0 nylon monofilament (Doccol corporation, 
USA), via the external carotid artery into the internal carotid artery in order to block the origin 
of the MCA according to the procedure originally described by Longa et al., (1989) and 
modified by Melani and co-workers (Melani et al., 1999) (Figure 30). 
In permanent middle cerebral artery occlusion (pMCAo), the nylon filament was not removed 
while in the transient (1 hour) model of focal cerebral ischemia (tMCAo), animals were re-
anesthetized with isoflurane and re-perfused by withdrawing the filament. The sham operation 
was conducted by inserting the filament into the internal carotid artery and immediately 
withdrawing it.  
 
 
Figure 30. Intraluminal middle cerebral artery occlusion. Abbreviations: ACA: anterior cerebral artery; 
ECA: external carotid artery; ICA: internal carotid artery; MCA: middle cerebral artery; PCOM: 
posterior communicating artery; PPA: pterygopalatine artery. From (Canazza et al., 2014). 
 
3.11 Chronic treatment with adenosine A2B receptor agonist, BAY60-6583 
3.11.1 Drug administration 
Adenosine A2B receptor agonist 2-[[6-Amino-3,5-dicyano-4-[4-(cyclopropylmethoxy) phenyl]-
2-pyridinyl] thio]-acetamide (BAY60-6583) (Tocris, Bristol, United Kingdom, UK) (Figure 
23), was dissolved in DMSO 0.1%. BAY60-6583 was chronically administered at the dose of 
0.1 mg/kg, intraperitoneally (i.p.) twice/day for 7 days. 
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3.11.2 Experimental groups 
A group of animals were subjected to transient middle cerebral artery occlusion (tMCAo) and 
sacrificed 7 days after tMCAo. Rats were randomly allocated in the following groups: (1) sham-
operated rats (n=7): did not receive any treatment; (2) tMCAo+vehicle group (n=6): saline with 
DMSO (0.1%) administered (i.p.) twice/day for 7 days, starting 4 hours after tMCAo; (3) 
tMCAo+BAY 60-6583 group (n=6): BAY60-6583 administered (i.p.) twice/day for 7 days, 
starting 4 hours after tMCAo. 
A second group of animals were subjected to tMCAo and sacrificed 2 days after tMCAo. Rats 
were randomly allocated in the following groups: (1) sham-operated rats (n=3): did not receive 
any treatment; (2) tMCAo+vehicle group (n=3): saline with DMSO (0.1%) administered (i.p.) 
twice/day for 2 days after tMCAo, starting 4 hours after tMCAo; (3) tMCAo+BAY 60-6583 
group (n=4): BAY60-6583 administered twice/day for 2 days after tMCAo, starting 4 hours 
after tMCAo.  
 
3.12 Sub-chronic treatment with Carbonic Anidrase inhibitors  
3.12.1 Drugs administration 
Acetazolamide (5-acetamido-1,3,4-thiadiazole-2-sulfonamide), (Figure 31) was dissolved in 
saline with 0.05% dimethyl sulfoxide (DMSO). Acetazolamide was sub-chronically 
administered at the dose of 4.4 mg/kg, i.p. 
AN11-740 was dissolved in saline with 0.01% DMSO. AN11-740 was sub-chronically 
administered at the dose of 1 mg/kg, i.p.  
 
Figure 31. Acetazolamide. 
 
3.12.2 Experimental groups 
Animals subject to pMCAo were sacrificed 24 hours after surgery. Rats were randomly 
allocated in the following groups: (1) sham-operated rats (n=7): did not receive any treatment; 
(2) pMCAo+vehicle group (n=4): saline+DMSO; (3) pMCAo+AN11-740 group (n=6); (4) 
pMCAo+AAZ group (n=4). The vehicle or both carbonic anidrase inhibitors were administered 
i.p. 5 minutes, 6 hours and 16 hours after occlusion.  
 
_________________________________________________________________ Materials and Methods 
66 
 
3.13 Neurological deficit 
The neurological deficit was evaluated by modified Neurological Severity Score (mNSS) test 
described by Chen et al., (2001). All tests were carried out before pMCAo or tMCAo and 1, 5 
and 7 days after MCAo. The mNSS test evaluates the sensorimotor deficit: it is composed of 
motor, sensory, reflex and beam balance tests (Figure 32). The score assigned to each rat at 
completion of the evaluation equals the sum of all test scores. The test is graded on a scale from 
0 (normal score) to 18 (maximal deficit score). In the beam balance test, a score between 0 
(normal score) and 6 (maximal deficit score) was assigned to each animal in function of the 
ability to stay and walk on the beam. Beam balance test score affects 1/3 of the total mNSS 
score. 
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Figure 32. Example of modified Neurological Severity Severity (mNSS) score points scale for 
sensorimotor deficit evaluation. 
 
3.14 Body weight evaluation 
Rats used to induce cerebral ischemia were in the body weight ranging from 270 to 290 g. The 
body weight was evaluated before pMCAo or tMCAo and after 1, 5, 7 days from occlusion. 
The weight variation after ischemia of each animal was evaluated with respect to its own pre-
ischemia weight. 
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3.15 Ischemic brain damage 
Rats were anesthetized with Zoletil 50/50 (100 mg/kg i.p., Virbac, Carros, Francia) and were 
perfused transcardially with an ice-cold 4% paraformaldehyde solution (in phosphate buffer, 
pH 7.4). Brains were post-fixed overnight and cryoprotected in a 18% sucrose solution (in 
phosphate buffer) for at least 48 hours. Brains were cut with a cryostat and coronal sections (30 
µm) were collected at 210 µm intervals at 12 different levels through the striatum (König and 
Klippel, 1967). One and seven days after pMCAo and tMCAo respectively, brain slices were 
stained by acetate cresyl violet (1%) or by hematoxylin and eosin (H&E). Histological analysis 
by cresyl violet staining allows to clearly define the infarct area and volume up to 1 week after 
ischemia (Rousselet et al., 2012). To evaluate area and volume of ischemic damage, 12 cresyl 
violet-stained brain sections per animal were placed directly on the scanning screen of a color 
flatbed scanner (CanoScan LiDE 90; Canon). Following image acquisition, the images were 
analyzed using ImageJ software. The measurements of infarct area in striatum and cortex were 
obtained by manually outlining the margins of infarcted area. Ischemic cortical and striatal 
volumes were calculated by multiplying the infarcted area by the slice thickness and summing 
the volume of the 12 slices. 
After H&E staining, heterochromatic nuclei were counted at Bregma level within an optical 
field at 40X in ischemic cortex and striatum. Data were then averaged and expressed as 
mean±SEM of number cells per optical field of “n” animals. 
 
3.16 Neuronal damage, gliosis and blood cell infiltration  
Immunohistochemistry was performed with the free-floating method (Giovannini et al., 2002; 
Lana et al., 2014) on rat brain coronal sections in striatum and cortex.  
The following primary antibodies were used: for neurons a mouse antineuronal nuclei (NeuN) 
antibody, dilution 1:400 (Product Code #MAB377, Millipore, Billerica, MA, United States); 
for astrocytes a mouse anti-GFAP antibody conjugated with the fluorochrome AlexaFluor 488, 
dilution 1:500 (Product Code #MAB3402X, Millipore, Billerica, MA, United States); for 
microglia a rabbit anti-ionized calcium binding adaptor molecule 1 (IBA1) antibody, dilution 
1:400 (Product Code #016-20001, WAKO, Osaka, Japan); for granulocytes a mouse 
monoclonal antibody anti-HIS-48, dilution 1:50 (Santa Cruz Biotechnology). The following 
fluorescent secondary antibodies were used: AlexaFluor 555 donkey anti-mouse, dilution 1:400 
(Product Code #A31570, Thermo Fisher Scientific); AlexaFluor 635 goat anti-rabbit, dilution 
1:400 (Product Code #A31577, Thermo Fisher Scientific). Nuclei were stained using DAPI, 
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contained in the mounting medium for glass slides, Vectashield (Product Code #H1200, Vector 
Laboratories, Burlingame, CA, United States). The sections were mounted onto gelatin-coated 
slides using Vectashield with DAPI (Vector Laboratories). Slices were observed with LEICA 
TCS SP5 a confocal laser scanning microscope (Leica Microsystems CMS GmbH, Manheim, 
Germany).  
 
3.16.1 Microscopy Techniques, qualitative and quantitative analysis 
The confocal microscopy images were obtained with a LEICA TCS SP5 confocal laser 
scanning microscope (Leica Microsystems CMS GmbH, Mannheim, Germany). The 
parameters of acquisition were maintained constant: frame dimension 1024 x 1024 points, 
frequency of acquisition 200 Hz. 
Two experimenters performed all quantitative analyses blind, and data were averaged. All 
evaluations of cell density were made on z projections of 10 consecutive confocal scans (total 
thickness 12 µm). Cells were counted, and the area of analysis was measured. Density of cells 
(neurons, astrocytes, microglial cells) was calculated as cells/mm2 in striatum and cortex, on 
confocal z projections of ten scans (total 12 µm inside the section). 
 
3.17 Determination of TNF-α and IL-10 plasma levels 
The levels of Tumor Necrosis Factor-α (TNF-α) pro-inflammatory cytokine and of interleukine-
10 (IL-10) a regulatory cytokine, were measured on aliquots (100µl) of plasma using 
commercial ELISA kits (Rat TNF-α Platinum ELISA, Catalogue no: BMS622, Affymetrix 
eBioscience, Vienna, Austria; Rat IL-10 Platinum ELISA, Catalogue no: BMS629, Affymetrix 
eBioscience, Vienna, Austria), following the protocol provided by the manufacturer. Results 
are expressed as pg of protein/ml of plasma. 
 
3.18 Statistical analysis 
Data were statistically analyzed by one-way analysis of variance (ANOVA) followed by 
Newman-Keuls multiple comparison test, Repeated Measures two-way analysis of variance 
(ANOVA) followed by Tukey post-hoc test and by unpaired Student's t test as specified in text 
and in figure legends. A value of p<0.05 was considered statistically significant. The statistical 
analysis was performed utilizing GraphPad Prism.
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Section I. Adenosine A2B receptor and SphK/S1P signaling axis 
control maturation of OPC in vitro. 
 
4.1 Adenosine A2B receptor activation stimulates SphK1 phosphorylation in 
cultured OPCs 
 
Electrophysiology experiments in our laboratory demonstrated that adenosine A2B receptor 
activation by 10µM BAY60-6583 inhibited voltage-dependent K+ currents in cultured OPCs. 
In the attempt to identify a putative cross-talk between A2B receptor and SphK/S1P signaling 
pathway, we studied whether an acute, 10 minutes, BAY60-6583 application (10 µM) in 
purified OPC cultures, could possibly affect the activation of one or both isoforms of SphK, 
SphK1 and SphK2, known to be expressed in oligodendroglial cells (Saini et al., 2005). Since it 
has been previously demonstrated that SphK1 and 2 activation require phosphorylation and then 
translocation to the plasma membrane, where the substrate is located (Pitson et al., 2003; Hait 
et al., 2007), we analyzed the phosphorylation of both enzymes after 10 minutes BAY60-6583 
challenge. Results presented here clearly show a significant increase in the phosphorylation of 
SphK1, but not SphK2, in cells exposed for 10 minutes to 10 µM BAY60-6583, as reported in 
Figure 33 (A and B). 
 
 
 
 
 
_____________________________________________________________________________ Results 
72 
 
 
Figure 33. The A2B receptor agonist BAY60-6583 stimulates SphK1 phosphorylation in cultured OPCs.  
A) Western Blot analysis of phospho-SphK1 (upper panel) and phospho-SphK2 (lower panel) in total 
cell lysates of OPC cultures demonstrates that 10 min application of 10 µM BAY60-6583 in cultured 
OPCs enhances SphK1 phosphorylation. B) In the histogram, band intensity corresponds to the 
phosphorylated form of SphK1 or SphK2 and is normalized to SphK1 or SphK2 total content. Data are 
mean ± SEM of three independent experiments, -fold change over control, set as 1. Densitometric 
analyses are reported as fold change above control (Ctrl). 
 
4.2 Adenosine A2B receptor and SphK activation modulate oligodendrocyte 
maturation in vitro. 
 
To study oligodendroglial cell maturation in vitro, OPC cells were led to differentiate into 
mature OLGs by growing for 3, 7 and 10 days in DM. As shown in figure 34 A, a significant 
and time dependent increase in MAG and Mbp expression was found, compared to OPC (open 
bar), that was maximal at 7 days (black bar). Moreover, we dissected the time-dependent 
expression of the adenosine A2B receptor in OLG compared to control OPC and found out that 
the expression of the receptor increases by the time of incubation with DM (Figure 34 B). The 
expression of A2B receptor was not affected by FTY720-P treatment, whereas, interestingly, it 
was dramatically decreased by a 7 days exposure to VPC96047 in respect to control untreated 
OLGs (black bar). Since S1P5 displays a time-dependent expression during OLG 
differentiation, we performed Real-Time PCR to measure S1P5 expression at 3, 7 and 10 days, 
and confirmed previous results reporting an increase of the receptor during differentiation from 
OPC towards OLG, turning to be the most expressed S1P receptor in mature OLGs (Yu et al., 
2004; Jung et al., 2007; Novgorodov et al., 2007).  
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Moreover, S1P5 mRNA levels were not significantly changed after 7 day-treatment with 
FTY720-P nor VPC96047 (Figure 34 C, orange bar, purple bar).   
 
 
Figure 34. Time course of oligodendrocyte marker expression, A2B receptor and S1P5 receptor during 
differentiation from OPC to OL. A) Gene expression analysis of oligodendrocyte differentiation markers 
MAG and Mbp was performed by Real Time-PCR in OPC and 3, 7 and 10 day-differentiation (OL 3d, 
7d, 10d) employing specific rat primers, as reported in table 3, using SYBR green probe. Each  
measurement was carried out in triplicate. The 2^(−ΔΔCT) method was applied as a comparative method 
of quantification and data were normalized to –actin expression. B) A2B receptor expression, analyzed 
employing specific rat primers and SYBR Green probe, was reported in OPC and after 3, 7, 10 days (t3, 
t7, t10) of DM, as 2^(-ΔΔCT) normalized to –actin and compared to the control OPC. OL 7d were 
challenge with or without 1 µM FTY720-P and 500 nM VPC96047 (FTY720-P 7d and VPC96047 7d). 
C) S1P5 receptor expression, analyzed employing specific rat primers, was reported as 2^-ΔΔCT, 
normalized to –actin. OL at t7 were challenge with or without 1 µM FTY720-P and 500 nM VPC96047 
(FTY720-P t7 and VPC96047 t7). Data are means ± SEM of three independent experiments performed 
in triplicate. Statistical analysis was performed using One-way ANOVA, followed by Bonferroni post-
hoc test, *p<0.05, **p<0.01, ***p<0.001. 
 
Finally, we investigated the involvement of the A2B receptor agonists in oligodendroglial cell 
maturation in vitro, alone or in combination with S1P analogues or SphK inhibitors.  
According to the results reported in the figure 34, we selected 7 days of DM as the reference 
time to analyze OPC differentiation under different conditions.  
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When OPCs were grown in DM for 7 days in the presence of the A2B receptor agonist BAY60-
6583 (10 µM), the compound prevented the increase of either MAG or Mbp expression in 
comparison to 7 day OLGs (Figure 35 A, red bar compared to open bar), indicating that A2B 
receptor stimulation counteracts OPC maturation towards OLGs. A similar result was obtained 
with the other A2B agonist, P453 (500nM) (Figure 35 A, brown bar). 
The opposite effect in comparison to A2B receptor stimulation was observed when OPCs were 
grown in the presence of the pan SphK-inhibitor VPC96047 or the selective SphK1-inhibitor 
VPC96091 (both at 500 nM, dark grey, dark green, respectively). In these two experimental 
groups, a further increase in MAG and Mbp expression was observed in comparison to 7 day 
OLGs, thus indicating that SphK inhibition promotes OPC maturation. Of note, neither of the 
two SphK inhibitors tested were able to prevent BAY60-6583- nor P453-mediated inhibition 
of OPC differentiation, demonstrating that A2B receptor stimulation overrides the pro-
differentiating effect of SphK inhibition.   
The S1P analogue FTY720-P, at a concentration of 1 µM, mimicked the effect of BAY60-6583 
in inhibiting oligodendroglial differentiation (Figure 35 A, purple bar).  
Among the S1P receptors possibly involved in modulating OPC maturation, we tested the role 
of S1P1 receptor by applying the selective S1P1 agonist SEW2871 (1 µM) and antagonist W146 
(10 µM). As reported in figure 35 B and C, neither of them affected OLG differentiation nor 10 
µM W146 ruling out a role for S1P1 in this process. 
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Figure 35. Adenosine A2B receptor and SphK/S1P mediated effects on oligodendrocyte differentiation 
in vitro. A) Gene expression analysis of oligodendrocyte differentiation markers MAG and Mbp by 
Realtime-PCR in OPC and after 7 days of DM (t7 OL) in the absence or presence of: BAY60-6583 (10 
µM), VPC96047 (500 nM), VPC96091 (500 nM), FTY720-P (1 µM) and P453 (500 nM). The 
quantification of MAG and Mbp mRNA was performed by Real-Time PCR employing specific primers 
as reported in materials and methods section using SYBR green probe. Each measurement was carried 
out in triplicate. The 2^(−ΔΔCT) method was applied as a comparative method of quantification and 
data were normalized to –actin expression. B) Gene expression analysis of oligodendrocyte 
differentiation markers MAG and Mbp by Realtime-PCR in OPC and after 7 days of DM (OL 7d) in the 
absence or presence of: BAY60-6583 (10 µM), SEW2871 (1 µM), W146 (10 µM). The quantification 
of MAG and Mbp mRNA was performed by Real-Time PCR as described above. Data are means ± 
SEM of three independent experiments performed in triplicate.  
Statistical analysis was performed by One-way ANOVA followed by Bonferroni post-hoc test: *p<0.05; 
**p<0.01; ***p<0.001. 
 
4.3 Effects of adenosine A2B receptor silencing on S1P pathway and 
oligodendrogenic differentiation. 
 
In order to clarify whether the effects on OPC maturation and differentiation can be attributed 
to A2B receptor-mediated effects, we performed A2B silencing by RNA interference. (Figure 
36).  
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After 48 hours silencing, about 50% A2B receptor was downregulated (p<0.01). Of note, A2B 
downregulation increased OPC differentiation (increase of CNPase, a myelin-marker and 
decrease of NG2 level) (p<0.05; p<0.001). These data consistent with our previous results 
demonstrating that A2B agonists inhibits OPC maturation towards OLGs. Moreover, cells 
transfected with A2B-siRNA showed a striking increase in S1P lyase levels, the enzyme 
responsible for of S1P catabolism (black bar, p<0.01). 
A2B downregulation also decreased S1P production (reduction of SphK levels, p<0.01) and 
S1P5 receptor expression (p<0.01). 
 
Figure 36. Adenosine A2B receptor silencing in cultured OPCs by small interference RNA (siRNA), 
facilitates cell maturation and interferes with S1P signaling. Relative quantitative mRNA analysis was 
performed by Real-Time PCR in OPC transfected with SCR-siRNA or with A2B-siRNA; the content of 
housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was analyzed in parallel.  
Results are expressed as fold changes according to the 2^-DDCT method, utilizing as calibrator the 
expression of each gene in scrambled siRNA-transfected cells. Data are means ± SEM of three 
independent experiments performed in triplicate. *p<0,05, **p<0,01, ***p<0,001; unpaired Student’s 
t-test.  
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Section II. Adenosine A2B receptor agonist, BAY60-6583, is 
protective in a rat model of transient cerebral ischemia. 
 
4.4 Effect of treatment with the adenosine A2B receptor agonist on neurological 
deficit after tMCAo 
 
Figure 37 A shows that in the mNSS test, sham-operated rats had a neurological score of 0.1-
0.6 in the period from 1 to 7 days after tMCAo, showing any neurological deficit. Twenty-four 
hours after tMCAo, vehicle-treated rats showed a clear neurological deficit with a neurological 
score of 10.6±0.9 (mean±SEM) that defines a moderate injury. The neurological impairment 
spontaneously recovered 5 and 7 days after tMCAo. Five days after tMCAo the neurological 
score was reduced to 6.6±0.7, seven days after tMCAo, the neurological score was further 
reduced to 5.8±1.1. Chronic treatment with the A2B agonist, BAY60-6583, at the dose of 0.1 
mg/kg, significantly reduced the neurological deficit at each time point after tMCAo. Repeated 
Measures two-way ANOVA calculated for the two factors: treatment and time after tMCAo, 
showed that treatment factor (F2,16=37.2; p<0.0001), time factor (F2,32=17.0; p<0.0001) and 
interaction between treatment and time (F4,32=3.9; p<0.009) were statistically significant. The 
Tukey post hoc test indicated that sham-operated rats had a neurological score significantly 
different from vehicle-treated and BAY60-6583-treated rats at each time point (1, 5, 7 days 
after tMCAo, p<0.0001-0.03). The chronic treatment with BAY60-6583 significantly reduced 
the neurological deficit with respect to vehicle-treated rats at 1, 5 and 7 days (p<0.0005-0.05) 
after tMCAo. 
 
4.5 Effect of treatment with the adenosine A2B receptor agonist on body weight 
loss after tMCAo. 
Twenty-four hours after operation, sham-operated rats were not affected in weight, then they 
increased in body weight as evaluated up to 7 days after tMCAo. On the contrary, vehicle-
treated rats lost 17.60±4.5 g 1 day after tMCAo, 14.0±3.6 g 5 days after tMCAo and 0.6±4.1 g 
7 days after tMCAo (Figure 37 B). Treatment with the A2B receptor agonist, BAY60-6583, did 
not significantly modify the body weight loss at any time point after tMCAo respect to vehicle-
treated rats. Repeated Measures two-way ANOVA, calculated for the two factors: treatment 
and time after tMCAo, showed that treatment factor (F2,15 = 29.7; p <0.0001), time factor (F2,30 
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= 68.5; p <0.0001) and the interaction between treatment and time (F4,30 = 13.7; p <0.0001) 
were statistically significant. The Tukey post hoc test indicated that in sham-operated rats, body 
weight was different with respect to vehicle-treated and BAY60-6583-treated rats at each time 
point (p <0.0001-0.0002) after tMCAo. 
  
Figure 37. Effect of chronic treatment with BAY60-6583 (0.1 mg/kg i.p.) on neurological deficit (A) 
and body weight loss (B). Data are expressed as mean±SEM of “n” rats. A) mNSS test: the score is 
evaluated before and after 1, 5 and 7 days from tMCAo in each rat group. Repeated Measures two-way 
ANOVA followed by Tukey post hoc test: #p<0.0001-0.03 sham-operated versus chronic BAY60-6583- 
and vehicle-treated rats; *p<0.0005-0.05 chronic BAY60-6583-treated versus vehicle-treated rats. B) 
Body weight loss: sham-operated rats increase their body weight in the period after the operation. The 
body weight loss of tMCAo rats was calculated as the mean±SEM of the difference between body weight 
at each time point and pre-operation body weight. Repeated Measures two-way ANOVA followed by 
Tukey post hoc test: #p<0.0001-0.0002 sham-operated versus chronic BAY60-6583 and vehicle-treated 
rats. 
 
4.6. Effect of treatment with the adenosine A2B receptor agonist on brain ischemic 
damage after tMCAo 
 
Figure 38 shows the extent of ischemic damage evaluated as infarct area (Figure 38 A, C) and 
infarct volume (Figure 38 B, D) in ischemic striatum and cortex of vehicle- and BAY60-6583-
treated rats 7 days after tMCAo.  
Chronic treatment with BAY60-6583, at the dose of 0.1 mg/kg significantly reduced the infarct 
in both areas. The striatal and cortical infarct volume were reduced by 44.7% and 46.3% 
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respectively. (Unpaired Student’s t-test: p<0.05-0.001; Figure 38 B, D). Sham-operated rats did 
not show any damage. 
 
 
 
Figure 38. Effect of chronic treatment with BAY60-6583 (0.1mg/kg) on infarct area (A, C) and infarct 
volume (B, D) in the striatum and cortex 7 days after tMCAo. Data are mean±SEM of infarct area 
measured at 12 predetermined coronal levels through the brain of “n” rats. Bregma=0 (König et al.,  
1964). Bar graphs show the infarct volume calculated as mean±SEM in the striatum and cortex. 
Unpaired Student’s t-test: *p<0.05; **p<0.001 vs vehicle-treated rats.  
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To characterize the cytoarchitecture of the ischemic cortex and striatum 7 days after tMCAo, 
ischemic tissue was stained by H&E (Figure 39 A-F). Seven days after transient ischemia, H&E 
staining showed a decrease in staining intensity in vehicle-treated rats (Figure 39 C, D) 
compared to the sham-operated rats (Figure 39 A, B). The typical cytoarchitecture of these two 
regions (for a description see Danner and Pfister, 1981) was lost. In the striatum, the white 
matter fascicula (f) were no more recognizable; in the fronto-parietal cortex the columnar 
organization was not appreciable and very numerous heterochromatic small nuclei were 
present. Figure 39 E, F shows that chronic administration of BAY60-6583 at the dose of 0.1 
mg/kg, was associated with a recovery of staining intensity and with a reduction of 
heterochromatic small nuclei staining in both brain regions.  
The cytoarchitecture of the white matter fascicula was recognizable in the dorsal corpus 
striatum (Figure 39 E) and the columnar organization was appreciable in the fronto-parietal 
cortex (Figure 39 F). Quantitative analysis showed that chronic BAY60-6583 treatment 
significantly reduced heterochromatic nuclei number in the ischemic striatum (p<0.01; Fig. 39 
G) and in the ischemic cortex (p<0.005; Fig. 39 H). 
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Figure 39. Effect of chronic treatment with BAY60-6583 (0.1 mg/kg i.p.) on cytoarchitecture of the 
ischemic striatum and cortex after tMCAo. Upper part: representative photomicrograph  of a histologica l 
section of control rat (at Bregma + 1.5mm) (König et al., 1964). The two white boxes indicate the 
ischemic striatal and cortical area reported in the magnifications. Scale bar=2mm). Sham-operated rats: 
(A) in the dorsal striatum, the typical caudate-putamen cytoarchitecture is appreciable, numerous 
transversally sectioned white matter fascicula (f) are surrounded by gray matter containing diverse type 
of neurons, distinct on the basis of their size and shape (Danner et al., 1981); (B) in the fronto-parietal 
cortex the typical columnar organization is appreciable. Vehicle-treated ischemic rats: (C) in most parts 
of the ischemic dorsal striatum, the cytoarchitecture is completely lost. The distinction between white 
and gray matter is no more appreciable; a remarkable increase of the interstitial spaces and numerous 
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heterochromatic small nuclei are present; (D) in the ischemic fronto-parietal cortex the columnar 
organization is hardly visible, the interstitial spaces are enlarged and dilatated and numerous 
heterochromatic small nuclei are present. BAY60-6583-treated ischemic rats: note the recovery of the 
staining intensity and the decrease of heterochromatic small nuclei; (E) in the ischemic dorsal striatum, 
the cytoarchitecture of the white matter fascicula is again recognizable; (F) in the ischemic fronto-
parietal cortex, the columnar organization is appreciable. Scale bar=100µm. Bar graphs represent the 
mean±SEM of the number of heterochromatic nuclei per optical field (40X) present at Bregma=0 
coronal level of three rats, in ischemic striatum (G) and ischemic cortex (H). Un paired Student’s t-test: 
*p<0.02; **p<0.005 vs. vehicle-treated rats.  
 
4.7 Effect of treatment with the adenosine A2B receptor agonist on neuronal 
damage in striatum after tMCAo 
 
To estimate the neuronal damage caused by tMCAo in the striatal boundary zone, we performed 
fluorescent confocal immunohistochemical analysis using neuron specific anti-NeuN antibody 
in control slices taken from sham-operated rats, in slices taken from vehicle-treated rats and in 
slices taken from BAY60-6583-treated rats. 
Representative images (each obtained stacking 10 consecutive confocal scans, z step of 1.2 µm, 
total thickness 12 µm) of NeuN immunostaining in the striatal boundary zone are shown in 
Figure 40 A-C. Figure 40 E shows the density of NeuN+ cells in the striatum of sham-operated, 
vehicle- and BAY60-6583-treated rats. Density of NeuN+ striatal neurons significantly 
decreased in vehicle-treated rats in comparison with sham-operated rats (*p<0.05).  
The treatment with BAY60-6583 reverted this effect in a statistically significant manner 
(#p<0.05). 
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Figure 40. Analysis of neurons in the striatal boundary zone of sham-operated, vehicle- and BAY60-
6583-treated rats 7 days after tMCAo. Schematic brain picture (D) indicate the region of interest (dark 
box) where microphotographs of ischemic boundary zone were captured. 
A-C: Representative confocal photomicrographs of NeuN immunostaining of neurons (red) in striatum 
of a sham (A), a vehicle (B) and a BAY60-6583 (C) rats. Scale bar: 100 μm. E: Quantitative analysis of 
neurons/mm2 in striatal boundary zone of sham, vehicle and BAY 60-6583-treated rats. Data reported 
in all graph bars are expressed as mean±SEM. One-way ANOVA and Newman-Keuls Multiple 
Comparison Test: *p<0.05, vehicle-treated rats vs sham-operated rats; #p<0.05 BAY60-6583-treated 
rats vs vehicle-treated rats. 
 
4.8 Characterization of neuronal damage in the striatum after tMCAo 
 
A closer examination of the neurons in the striatal boundary zone with confocal microscopy 
indicated the presence of many damaged neurons in both vehicle- and BAY60-6583-treated rats 
seven days after tMCAo. Representative images (each obtained stacking 10 consecutive 
confocal scans, z step 1.2 µm each, total thickness 12µm) of NeuN immunostaining in the 
striatal boundary zone are shown in Figure 41 A-C.  Magnifications of the framed areas, shown 
in figure 41 B1-C1, shows the altered morphology of striatal neurons after tMCAo, in 
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comparison to those of the sham-operated rat as shown in panel 41 A1. Indeed, in the striatal 
boundary zone of vehicle- and BAY60-6583-treated rats, we observed many NeuN+ neurons 
that lost their NeuN+ nuclear immunofluorescence, an index of damaged nuclei, while NeuN+ 
immunofluorescence persisted in the cytoplasm (Figure 41, white arrows). We defined these 
neurons as Low Density Nucleus neurons, “LDN neurons” (Fusco et al., 2018). It has been 
demonstrated that these damaged neurons are apoptotic thanks to cytochrome C staining (Fusco 
et al., 2018).  
In order to better characterize this phenomenon, we performed the quantitative analysis of LDN 
neurons in sham-operated, vehicle- and BAY60-6583-treated rats (Figure 41 E).  
This analysis demonstrated that the percentage of LDN neurons was significantly increased in 
vehicle-treated rats compared with sham-operated rats (**p<0.01 vehicle-treated vs sham-
operated rats). Furthermore BAY60-6583 significantly reverted the percentage increase in 
comparison to vehicle treated rats (#p<0.05 BAY60-6583-treated vs vehicle-treated rats). 
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Figure 41. Analysis of damaged neurons in striatum 7 days after tMCAo. Schematic brain picture (D) 
indicate the region of interest (dark box) where microphotographs of ischemic boundary zone were 
captured. A-C1: Representative confocal microphotographs of NeuN immunostaining of neurons (red) 
in the striatal boundary zone of sham-operated (A), vehicle- (B), and a BAY 60-6583-treated (C) rats. 
Scale bar: 40 μm. Panels A1, B1 and C1 shows the magnification of neurons framed in Panels A, B and 
C. Scale bar: 10 μm. Note the presence of many LDN neurons (open arrows) in the striatum of vehicle 
(B1) and BAY60-6583 (C1). E: Quantitative analysis of percent of LDN neurons on total neurons. 
Percent of LDN neurons was significantly higher in striatum of vehicle vs sham rats. BAY60-6583 
reverted this significant increase. All data in the graphs are expressed as mean±SEM. One-way ANOVA 
and Newman Multiple Comparison Test, **p<0.01 vehicle vs sham-operated rats; #p<0.05 BAY60-
6583-treated rats vs vehicle-treated rats. 
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4.9 Effect of treatment with the adenosine A2B receptor agonist on microglia 
morphology in the striatum after tMCAo 
 
Total microglia cells were identified in the striatal boundary zone using the fluorescent 
immunostaining for IBA1, as shown by the representative images of Figure 42 A-C, each 
obtained stacking 10 consecutive confocal z scans (1.2µm each, total thickness 12 µm) through 
the thickness of striatal boundary zone. Figure 42 shows the magnifications of the framed areas 
in panels A1-C1. Quantitative analysis of IBA1-positive cells in Figure 42 E revealed that 
microglia cells increase in vehicle-treated rats in comparison with sham-operated rats (+95% 
vehicle vs sham) 7 days after tMCAo, although not in a statistically significant manner. The 
qualitative analysis shows that in vehicle-treated rats there is a strong pattern of microglia 
activation (magnification B1): microglial cells appeared with hypertrophic branches, round-
shaped and ameboid morphology in comparison with those of sham-operated rats, that are in a 
resting ramified state (Figure 42 A1). BAY60-6583 reverted these morphological changes 
reducing the strong pattern of activation. As shown in figure C1, microglia cells belonging to 
BAY60-6583-treated rats have similar morphology to that of sham-operated rats (Figure A1).   
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Figure 42. Analysis of microglia in the striatal boundary zone of sham-operated, vehicle- and BAY 60-
6583-treated rats 7 days after tMCAo. Schematic brain picture (D) indicate the region of interest (dark 
box) where microphotographs of ischemic boundary zone were captured. A-C1: Representative confocal 
photomicrographs of IBA1 immunostaining of microglia (white) in striatal boundary zone of sham-
operated (A), vehicle- (B) and BAY60-6583-treated rats (C). Scale bar: 100 μm. Panels A1, B1 and C1 
show the magnification of neurons framed in Panels A, B and C. Scale bar: 10 μm. E: Quantitative 
analysis of IBA1 positive microglia/mm2 in striatal boundary zone of sham-operated, vehicle- and 
BAY60-6583-treated rats. All data in the graphs are expressed as mean±SEM. 
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4.10 Effect of treatment with the adenosine A2B receptor agonist on astrocytes 
morphology in the striatum after tMCAo 
Astrocytes were immunolabelled in the striatal boundary zone with anti-GFAP antibody.  
Figure 43 A-C show the representative images, each obtained stacking 10 consecutive confocal 
z scans (1.2 µm each, total thickness 12 µm) through the thickness of striatal boundary zone.  
Panels 43 A1-C1 show the magnifications of the framed areas in figures 43 A-C. Figure 43 B1 
shows that 7 days after tMCAo the density and morphology of striatal astrocytes of vehicle-
treated rats was significantly different from that of the sham-operated rats (Figure 43 A1). 
Indeed, in vehicle-treated rats, astrocytes morphology is strongly altered: they are smaller with 
shorter and highly fragmented branches. Chronic treatment with BAY60-6583, at the dose of 
0.1 mg/kg, reverted the alterations caused by ischemia in the morphology of astrocytes (Figure 
43 C1):   astrocytes in BAY60-6583-treated rats show a morphology mostly similar to that of 
sham-operated rats.  
Quantitative analysis of GFAP+ astrocytes reported in Figure 43 E, shows that the density of 
GFAP+ astrocytes decreased significantly (-75% vehicle-treated rats vs sham-operated rats) in 
vehicle-treated rats in comparison to sham-operated rats (*p<0.05 vehicle-treated vs sham-
operated rats). In slices taken from BAY60-6583-treated rats, the loss of astrocytes was reduced 
(-32% BAY60-6583-treated rats vs sham-operated rats) although the difference respect to 
vehicle-treated rats was not different in a statistically significant manner. 
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Figure 43. Analysis of astrocytes in striatal boundary zone of sham-operated, vehicle- and BAY60-
6583- treated rats 7 days after ischemia. Schematic brain picture (D) indicate the region of interest (dark 
box) where microphotographs of ischemic boundary zone were captured. A-C: Representative confocal 
photomicrographs of GFAP immunostaining of astrocytes (green) in the striatum of a sham-operated 
(A), vehicle- (B), and a BAY60-6583- (C) treated rats. Scale bar: 100 μm. Panels A1, B1 and C1 show 
the magnification of areas framed in panels A, B and C. Scale bar: 10 μm. E: Quantitative analysis of 
GFAP positive astrocytes/mm2 in striatum of sham vehicle and BAY60-6583 treated rats. Astrocytes 
were significantly less numerous in striatum of vehicle vs sham rats: One-way ANOVA and Newman 
Multiple Comparison Test, *p<0.05 vehicle-treated vs sham-operated. All data in the graphs are 
expressed as mean±SEM. 
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4.11 Effect of treatment with the adenosine A2B receptor agonist on cytokines 
plasma levels after tMCAo. 
Seven days after tMCAo, plasma levels of pro-inflammatory cytokine TNF-α were significantly 
increased in vehicle-treated rats as compared to sham-operated rats (One-way ANOVA: 
p<0.01; Figure 44 A), while the plasma level of IL-10, a regulatory cytokine with anti-
inflammatory action was reduced in vehicle-treated rats as compared to sham-operated rats 
(Figure 44 B). Chronic treatment with BAY60-6583, at the dose of 0.1 mg/kg, significantly 
decrease TNF-α levels and significantly increase the plasma level of IL-10 (One-way ANOVA: 
p<0.001-0.01). 
 
Figure 44. Effect of chronic treatment with BAY60-6583 (0.1 mg/kg i.p.) on TNF-α (A) and IL-10 (B) 
plasma levels. Results are expressed as pg of protein/ml of plasma and values are mean±SEM. One-way 
ANOVA: #p<0.01 vs sham-operated rats; *p<0.01; **p<0.001vs vehicle-treated rats. 
 
4.12 Effect of treatment with the adenosine A2B receptor agonist on blood cell 
infiltration after tMCAo. 
Two days after tMCAo, HIS-48-positive cells (granulocytes) were detected in the cortical and 
striatal ischemic core (Figure 45), while seven days after ischemia, granulocytes were anymore 
detectable in the ischemic tissue (data not shown). No HIS-48-positive cells were present in the 
cortical and striatal tissue of sham-operated rats.  
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Chronic treatment with BAY60-6583 (0.1 mg/kg) clearly reduced HIS-48-positive cells in 
cortex and to some extent also in the striatum core. The number of HIS-48-positive cells was 
reduced in a statistically significant way in cortical ischemic core after treatment with BAY60-
6583 (mean±SEM.: 121.2±4.2 cells/optical field in vehicle- vs 93.3±3.7 cells/optical field in 
BAY60-6583-treated rats; Unpaired Student’s t test: p<0.004), but not in the striatal ischemic 
core (mean±SEM.: 104.05±8.61 cells/optical field in vehicle- vs 90.4±4.3cells/optical field in 
BAY60-6583 -treated rats; Unpaired Student’s t test: p<0.18) (Figure 45 B). 
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Figure 45. A: representative microphotographs of HIS-48 positive cells detected in the striatal and 
cortical core of sham-operated, vehicle-and BAY60-6583-treated rats acquired with Olympus BX63 
microscope equipped with CellSens Dimension software (Olympus, Germany) at 20X magnificat ion. 
Scale bar: 50µm. BAY60-6583 reduces HIS-48-positive cells in cortex and striatum. B: Bar graphs 
represent the mean±SEM of the number of HIS-48 positive cells per optical field (20X) counted in seven 
coronal levels through the brain of “n” rats taking Bregma=0 (König et al., 1964) in ischemic striatum 
and in ischemic cortex. Unpaired Student’s t-test: **p<0.004. 
 
 
_____________________________________________________________________________ Results 
93 
 
Section III. Carbonic Anhydrase Inhibitors (CAIs) for 
management of cerebral ischemia  
 
4.13 Effect of treatment with CAIs on neurological deficit after pMCAo. 
The mNSS test was performed according to Chen et al. (2001) before and 24 hours after 
pMCAo. Figure 46 shows that sham-operated rats had a neurological score of 0.6±0.3, 24 hours 
after pMCAo. Twenty-four hours after pMCAo, vehicle-treated rats showed a clear 
neurological deficit with a neurological score of 14.0±0.7 (mean±SEM) that defines a severe 
injury. Sub-chronic treatment with both carbonic anhydrase inhibitors, acetazolamide (4.4 
mg/kg i.p.) and AN11-740 (1.0 mg/kg i.p.) respectively, reduced by 28.6% and by 41.4% 
respectively the neurological deficit 24 hours after pMCAo (One-way ANOVA: p<0.001-
0.0001) in a statistically significant manner. 
 
Figure 46. Effect of sub-chronic treatment with acetazolamide and AN11-740 on neurological deficit.  
Data are expressed as mean±SEM of “n” rats. mNSS test: the score is evaluated before and after 24 
hours from pMCAo in each rat group. One-way ANOVA: **p<0.001-***p<0.0001 vs vehicle-treated 
rats. 
 
4.14 Effect of treatment with CAIs on brain ischemic damage after pMCAo. 
Figure 47 shows the extent of ischemic damage evaluated as infarct area (Figure 47 A, C) and 
infarct volume (Figure 47 B, D) in ischemic striatum and cortex of vehicle-, acetazolamide and 
AN11-740-treated rats 24 hours after pMCAo. Sub-chronic treatment with both acetazolamide 
(4.4 mg/kg i.p.) and AN11-740 (1.0 mg/kg i.p.) significantly reduced the infarct volume in 
ischemic cortex by 72.4% and 83.7%, respectively (One-way ANOVA: p<0.001) and in 
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ischemic striatum by 48.1% and 54.1%, respectively (One-way ANOVA: p<0.001). Sham-
operated rats did not show any damage. 
 
 
 
Figure 47. Effect of sub-chronic treatment with acetazolamide and AN11-740 on infarct area (A, C) 
and infarct volume (B, D) in the cortex and striatum 24 hours after pMCAo. Data are mean±SEM of 
infarct area measured at 12 predetermined coronal levels through the brain of “n” rats. Bregma=0 (König 
et al., 1964). Bar graphs show the infarct volume calculated as mean±SEM in the striatum and cortex. 
One-way ANOVA: *p<0.01- **p<0.001 vs vehicle-treated rats. 
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4.15 Effect of treatment with CAIs on neuronal damage after pMCAo. 
Twenty-four hours after pMCAo, the extent of neuronal damage in ischemic striatum and cortex 
was assessed by immunohistochemistry using anti-NeuN antibody. Representative images of 
NeuN immunostaining of each group were shown in figure 48 A-H. Twenty-four hours after 
pMCAo, NeuN+ cells decreased in both ischemic areas in vehicle-treated rats (Figure 48 C-D).  
Quantitative analysis (Figure 48 I-L) demonstrated that sub-chronic treatment with 
acetazolamide and AN11-740 significantly increased the number on NeuN+ cells in ischemic 
cortex (mean±SEM.: 81.75±4.4 cells/optical field in vehicle- vs 158±34.7 cells/optical field in 
acetazolamide-treated rats and vs 132±8.4 cells/optical field in AN11-740-treated rats, One-
way ANOVA: p<0.01) and also in the ischemic striatum (mean±SEM.: 90±11.6 cells/optical 
field in vehicle- vs 146±3.6 cells/optical field in acetazolamide-treated rats and vs 148.3±20.6 
cells/optical field in AN11-740-treated rats, One-way ANOVA:p<0.01). 
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Figure 48. Effect of sub-chronic treatment with acetazolamide and AN11-740 on neuronal damage in 
cortex and striatum 24 hours after pMCAo. Upper part: schematic brain picture indicates the regions of 
interest (dark box) where microphotographs of ischemic core in cortex and striatum were captured.  
A-H: representative microphotographs of neurons (red) cortex and in striatum of sham-operated (A-B), 
vehicle- (C-D) acetazolamide-(E-F) and AN11-740-(G-H) treated rats acquired with Olympus BX63 
microscope equipped with Cell-Sens Dimension software (Olympus, Germany). I-L: quantitative 
analysis of number NeuN positive cells in ischemic cortex and striatum. Bar graphs represent 
mean±SEM of the number of neurons per optical field (20X). One-way ANOVA: *p<0.01 vs vehicle-
treated rats. 
 
4.16 Effect of treatment with CAIs on cytokines plasma levels after pMCAo. 
Twenty-four hours after pMCAo, we evaluated plasma levels of pro-inflammatory cytokine 
TNF-α. In vehicle-treated rats TNF-α plasma levels significantly increased as compared to 
sham-operated rats (one-way ANOVA: p<0.001; Figure 49 A) while the plasma level of IL-10, 
a regulatory cytokine with anti-inflammatory action was reduced in vehicle-treated rats as 
compared to sham-operated rats (Figure 49 B). Sub-chronic treatment with both carbonic 
anhydrase inhibitors, acetazolamide and AN11-740, at the dose of 4.4 mg/kg and 1.0 mg/kg, 
respectively, didn’t modify neither TNF-α nor IL-10 plasma levels 24 hours after pMCAo 
(Figure 49 B). 
 
Figure 49. Effect of sub-chronic treatment with acetazolamide and AN11-740 on TNF-α (A) and IL-10 
(B) plasma levels. Results are expressed as pg of protein/ml of plasma and values are mean±SEM. One-
way ANOVA: **p<0.001 vs sham-operated rats.
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Section I. Adenosine A2B receptor and SphK/S1P signaling axis 
control maturation of OPC in vitro. 
The present work provides the first description of a role of adenosine A2B receptor subtype in 
oligodendroglial cell cultures. 
Adenosine is known to participate to a number of OPC functions, from cell migration to myelin 
production (Fields et al., 2002; Coppi et al., 2015). Our group recently contributed to address 
this issue by demonstrating that adenosine A2A receptor stimulation counteracts 
oligodendroglial cell differentiation in vitro by inhibiting outward sustained IK currents in 
cultured OPCs, which are known to be necessary to OPC differentiation (Gallo et al., 1996).  
In the present work, we demonstrate that also A2B receptor subtype is involved in OPC 
maturation: indeed, the selective A2B agonist, BAY60-6583 at 10µM concentration, inhibited 
in vitro OPC differentiation when added for 7 days in the culture medium of these cells. 
The SphK/S1P signaling pathway is known to be a pleiotropic mechanism in modulating a 
variety of cell functions, also in the oligodendroglial lineage. 
It has already been shown that these two signaling pathways, A2B receptor and SphK/S1P, 
interact in a different cell system (i.e. human erythrocytes) (Sun et al., 2015). 
We provide here the first demonstration of an interplay between SphK and adenosine A2B 
receptor activation in OPC maturation in vitro, since an acute application of the A2B receptor 
agonist BAY60-6583 promotes SphK1 phosphorylation. The effect was specific on this enzyme 
isoform because no differences were found in the phosphorylated form of SphK2. 
We focused on elucidating the functional role of SphK1/A2B receptor interaction through the 
use of SphK or S1P receptor ligands. 
We found that the two SphK inhibitors tested, VPC96047 (which affect both isoforms, SphK1 
and 2) and VPC96091 (that selectively inhibits SphK1), prompted OPC development into 
myelin-producing cells, because the expression of myelin markers such as MAG and Mbp after 
7 days of in vitro differentiation was increased when oligodendroglial cultures were grown in 
the presence of these compounds. Of note, the effect of unselective SphK inhibitor VPC96047, 
which prevents both SphK1 and SphK2 activation, was much more pronounced than that 
obtained in the presence of selective SphK1 inhibitor VPC96091, indicating an involvement of 
both enzyme isoforms in OPC maturation. This result is in accordance with previous works 
demonstrating that the mitogenic effect of PDGF in these cells requires is mediated by the 
activation of SphK (Soliven et al., 2003). Of note, when cells were grown in the presence of 
BAY60-6583 co-applied with either of the two SphK inhibitors, the effect of BAY60-6583 
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prevailed since OPC differentiation was inhibited. This result indicates that SphK activation is 
not required for A2B-mediated signaling. 
To date, among S1P receptors, we do not have a valid candidate to be involved in OPC 
maturation. We can only rule out the involvement of S1P1 subtype since neither selective 
agonism nor antagonism was found to affect OPC maturation nor to counteract A2B-mediated 
effects. 
An additional proof that A2B receptors are critical modulators of OPC maturation resides in the 
fact that this receptor subtype is upregulated during cell differentiation. Interestingly, SphK 
inhibition potently reduced A2B mRNA levels in OPCs at 7 days of differentiation. This result 
confirms that a cross-talk exists between A2B and SphK/S1P pathways and indicates a possible 
positive effect of the sphingolipid on A2B receptor expression. 
S1P5 receptor is also overexpressed during oligodendrogliogenesis but, differently from A2B, its 
upregulation is not modified by VPC96047.  
FTY720 is the first oral MS therapeutic agent and the first human medicine to be approved that 
targets S1P receptors. Emerging evidence from preclinical studies demonstrate that 
mechanisms independent of peripheral immune effects contribute significantly to the efficacy 
of FTY720 in models of MS. Indeed, FTY720, which is lipophilic, is able to cross the BBB into 
the CNS and after its conversion by SphK2, FTY720-P has been detected in the cerebrospinal 
fluid at sub-nanomolar levels (Foster et al., 2007). In addition, recent data using neural lineages 
from conditional S1P1 knockout demonstrated a crucial action of FTY720 in reducing the 
severity of an animal model of MS, EAE.  
Results from in vitro studies have shown that the effects of FTY720-P on cultured 
oligodendrocyte lineage cells are affected by developmental stage, treatment concentration and 
duration (Novgorodov et al., 2007; Miron et al., 2008). Cultured rodent OPC treated with 
FTY720 are protected from apoptosis induced by inflammatory cytokines and microglial 
activation (Coelho et al., 2007).  
The differentiation of OPC in our model is reduced after the treatment with high (µM) 
concentrations of FTY720-P in agreement with previous results obtained in rat cultured OPCs 
(Coelho et al., 2007; Miron et al., 2008).  
In order to further clarify the effect of the A2B receptor activation on OPC maturation and its 
interaction with SphK/S1P pathway, we performed the silencing of A2B receptor in OPC cells 
culture by RNA interference (RNAi). As reported by RT-PCR, transfected cells showed 
specific silencing of the A2B receptor gene. These results show that RNA silencing of the A2B 
receptor gene changed S1P pathway by increasing S1P lyase level and decreasing S1P3, S1P5 
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and ShpK1 expression. Moreover, A2B silencing also accelerated OPC maturation, as 
demonstrated by the significant decrease of NG2 (which labels undifferentiated OPCs) and 
increase of CNPase (which labels post-mitotic OLGs) expressions. These results are consistent 
with the fact that A2B agonist inhibit oligodendroglial maturation.  
To date this is the first characterization of the role of adenosine A2B receptor in oligodendrocyte 
cells in which we demonstrated that a direct cross-talk exists between A2B receptor and 
SphK/S1P signaling axis in inhibiting OPC maturation. Further investigations will be needed 
in order to clarify the molecular mechanism involved. 
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Section II. Adenosine A2B receptor agonist, BAY60-6583, is 
protective in a rat model of transient cerebral ischemia. 
 
Our results demonstrate that the selective adenosine A2B receptor agonist, BAY60-6583, 
chronically and systemically administered improves the neurological deficit, reduces the 
ischemic brain damage, counteract the neurodegeneration, and microglia activation and tend to 
protect from astrocyte death seven days after tMCAo. Moreover, BAY60-6583 reduces blood 
cell infiltration in ischemic areas two days after tMCAo. 
The chronic treatment with BAY60-6583 at the dose of 0.1 mg/kg protects from the 
neurological deficit as evaluated up 7 days after tMCAo but does not protect ischemic rats from 
the body weight loss. On this regard it is worth mentioning that adenosine released from fat 
cells in adipose tissue (Schwabe et al., 1975; Capogrossi et al., 1986) participates in the 
regulation of adipocyte function (Eisenstein et al., 2014). In particular, stimulation of A2B 
receptor inhibits adipogenesis (Gharibi et al., 2012). This effect might account for the lack of 
the chronic treatment with BAY60-6583 in protecting from the body weight loss.  
BAY60-6583 reduces significantly the volume of the ischemic infarct both in the cortex and 
striatum. Immunohistochemical analysis of neurons, in the striatum of ischemic rats, 7 days 
after MCAo induction revealed remarkable alterations in comparison with sham-operated rats. 
We found a significant decrease of total neuron density and a significative increment of the 
low-density nuclei (LDN) neurons. Fusco and colleagues (Fusco et al., 2018) had characterized 
LDN neurons as damaged and apoptotic neurons, a clear sign of an ischemic insult. BAY60-
6583 significantly prevented the loss of neurons and reduced the percent of LDN neurons on 
total neurons, a clear sign of its protective role against neurodegeneration. Indeed, seven days 
after ischemia, H&E staining shows that chronic treatment with BAY60-6583 has reconstituted 
the cortex and striatum cytoarchitecture and has decreased heterochromatic small nuclei in the 
ischemic area. Melani et colleagues (Melani et al., 2014) have reported that 7 days after 
ischemia the heterochromatic small nuclei belong to activated astrocytes and microglia. It is 
today well known that after an ischemic event, over-activation of microglia is detrimental and 
these resident immune cells are involved in the neuroinflammation process (Schwartz, 2003; 
Kriz, 2006; Block et al., 2007). Seven days after ischemia, the chronic treatment of BAY60-
6583 has definitely reduced the morphological features of microglia activation (i.e. the 
amoeboid state). Adenosine A2B receptor is expressed on microglia and their stimulation 
reduces TNF-α levels in primary microglia cultures (Merighi et al., 2015) and augments the 
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release of IL-10 by murine microglial cells (Koscsó et al., 2012). Moreover, adenosine A2B 
receptor is also expressed on astrocytes where its levels increase 24 hours after transient 
ischemia (Li et al., 2017). The chronic treatment of BAY60-6583 tended to decrease the loss of 
astrocytic cells. In a model in vitro of hypoxia/reoxygenation, A2B receptor stimulates the 
increase of IL-6 from astrocytes (Maeda et al., 1994) and it was demonstrated that IL-6 exerts 
neuroprotective actions in a model of permanent MCAo (Loddick et al., 1998). Interestingly, 
analysis of astrocytes gave an unexpected result: after ischemia, astrocytes density decreased 
and their morphology was altered with shorter and thinner branches, suggesting a 
clasmatodendrotic process.  
Astrocyte clasmatodendrosis is induced in vitro by mild acidosis, a microenvironmental 
condition commonly associated with aging (Mercatelli et al., 2016) and ischemia (Hulse et al., 
2001). BAY60-6583 showed a tendency to revert this effect. Further analyses are necessary to 
better investigate this phaenomenon. On the all, the previous observations support that the 
protective effect of chronic BAY60-6583 treatment along the days after ischemia can be 
attributed to direct agonism of A2B receptor located on rat microglial cells and on astrocytes 
cells.  
Besides microglia and astrocytes, A2B receptor is present also on endothelial cells where their 
expression increases after transient ischemia (Li et al., 2017). It has been reported that 
stimulation of A2B receptor reduces vascular leak in a model of hypoxia in mice (Eckle et al., 
2008 a). After ischemia, it is known that damage evolves in time and space (Dirnagl et al., 1999) 
and it is today accepted that after a first excitotoxic damage, a secondary damage characterized 
by neuroinflammation  further damages the brain tissue. In the days after ischemia, activated 
blood cells infiltrate brain tissue and by secreting cytotoxic factors contribute to further enlarge 
the ischemic damage. A2B receptor localized on blood immune cells, i.e. neutrophils and 
lymphocytes (Gessi et al., 2005; Eckle et al., 2008 a) exert anti-inflammatory actions, inhibiting 
vascular adhesion (Yang et al., 2006) and inflammatory cells migration (Wakai et al., 2001; 
Konrad et al., 2012).  
Our observation that 2 days after tMCAo the A2B agonist, BAY60-6583, has significantly 
reduced granulocyte infiltration in cortex, supports that A2B receptor activation on endothelial 
and blood cells is involved in counteracting neutrophils infiltration and then inflammation of 
brain parenchyma. In agreement A2B receptor KO mice, exposed to hypoxia, exhibit increased 
neutrophils infiltration in the brain (Eckle et al., 2007 a, 2008 a).  
Interestingly, seven days after ischemia an inflammatory parameter such as TNF-α is increased 
in the peripheral plasma and that chronic administration of the adenosine A2B receptor agonist, 
__________________________________________________________________________ Discussion 
104 
 
BAY60-6583, clearly reduced TNF-α in the plasma. Such reduction might reflect a central 
effect of BAY60-6583 that reduces pro-inflammatory cytokine produced in the brain and 
reaching peripheral blood. It is also possible that TNF-α reduction in the plasma reflect a direct 
peripheral mechanism of action of BAY60-6583 that reduces neutrophils activation. On the 
other hand, stroke and inflammation are strictly interrelated. Brain ischemia induces profound 
inflammatory changes in the periphery (Szigeti et al., 2015). Inflammatory changes in 
peripheral organs (especially the lungs and the gut) as early as 2 hours after tMCAo in mice, 
has been detected by whole-body-SPECT-based imaging protocol (Szigeti et al., 2015).  
Such peripheral inflammatory changes on their turn might contribute to a worse recovery after 
stroke. The precise cellular-molecular mechanisms underlying are unclear, but likely reflect a 
vicious circle responsible of inflammatory mediator production and of the blood brain barrier 
(BBB) function. Overall our results stress the key research questions of the predictive value of 
blood biomarkers in stroke and suggest that BAY60-6583 by controlling a secondary 
inflammatory damage, represents a new interesting target after brain ischemia. 
A previous study has reported that intravenous treatment with the selective A2B receptor agonist 
BAY60-6583 (1 mg/kg), at the start of reperfusion after brain ischemia induced by tMCAO, at 
an early time after ischemia, that is 24 hours later, has reduced the lesion volume, has attenuated 
brain swelling and BBB disruption. In the presence of tPA (administered after ischemic stroke 
to dissolve intravascular clots), BAY 60-6583 also has reduced tPA induced haemorrhages after 
ischemia (Li et al., 2017). The neurovascular protection afforded by BAY 60-6583 was related 
to stimulation of the inhibitor of matrix, the metalloproteinase-1 (TIMP-1), to inhibition of tPA-
induced matrix metalloprotease (MMP) activation, and prevention of tight junction protein 
degradation. Since MMPs by degradation extracellular matrix complex and tight junction 
proteins on endothelial cells (Tsuji et al., 2005; Yepes et al., 2009), can increase BBB 
permeability, protection afforded by A2B agonist after MCAo was largely attributed to 
protection of the endothelium. 
The present study points toward the possibility that stimulation of adenosine A2B receptors 
located on central neural cells, on vascular cells and on blood cells attenuate neuroinflammation 
that develops days after ischemia. Importantly, A2B receptor agonists might be adjuvant to the 
today accepted pharmacological strategy of tPA administration, a promising strategy for 
decreasing the risk of haemorrhages during treatment for ischemic stroke. 
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Section III. Carbonic Anhydrase Inhibitors (CAIs) for 
management of cerebral ischemia. 
 
In this work, we report that the two carbonic anhydrase inhibitors (CAIs) acetazolamide and 
AN11-740, sub-chronically administered at the dose of 4.4 mg/kg i.p and 1.0 mg/kg i.p. 
respectively, improve neurological deficit and reduce ischemic brain damage 24 hours after 
pMCAo in the rat.  
A previous paper reported that several inhibitors of CA were able to reduce neurological deficit 
but not significantly the ischemic damage 24 hours after pMCAo (Di Cesare Mannelli et al., 
2016). Results obtained in the present work show, 24 hours after pMCAo, a definite volume 
damage in striatum and cortex. In the same areas, the immunohistochemical analysis revealed 
a clear decrease of neuron number. Acetazolamide and AN11-740 have clearly protected 
neurons from damage and from the decrease in number of neurons. Protection is definite in the 
cortex and in striatum.   
Evidence that hypoxic microenvironments elicit the expression of specific isoforms of CA (in 
particular CA IX and CA XII)  through the hypoxia inducible factor (Wykoff et al., 2000) stress 
the relevance of CA in ischemia and supports the importance of  CAIs as protective drugs after 
ischemia. Indeed, under ischemia, the lack of oxygen caused by hypoxia leads to a switch from 
aerobic to anaerobic glucose metabolism, characterized by increased production of lactic acid 
and a lowered intracellular pH (Swietach et al., 2007) in neurons and glial cells (Obara et al., 
2008). CA isoforms, IX and XII are highly concentrated in glial cells both intracellularly and 
membrane-bound (Tong et al., 2000; Svichar et al., 2006) and  contribute to pH regulation both 
in physiological and pathological conditions. Astrocytes act as key players in pH homeostasis 
in the brain (Bélanger et al., 2009). Glial CA converts neuron derived CO2 to bicarbonate and 
protons which are driven out of the glial cell by a Na+/HCO3 co-transporter and 
monocarboxylate transporters. In the extracellular space, CA catalyzes the reaction of 
bicarbonate with a proton to recycle CO2, which is instrumental for buffering extracellular pH 
(Tong et al., 2000). A pH dysregulation has been related to a spectrum of pathological 
conditions (Obara et al., 2008). CAIs by reducing H+ concentration and thus contributing to the 
pH homeostasis (Supuran, 2008; Pettersen et al., 2015) can protects from damage especially 
neurons which are particularly sensitive to pH decrease (Obara et al., 2008). 
Maintenance of pH homeostasis in the CNS is of key importance for proper execution and 
regulation of neurotransmission, and deviations from this homeostasis is a crucial factor in the 
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mechanism underlying a spectrum of pathological conditions (Obara et al., 2008). It is known 
that changes in the intracellular concentration of protons may affect the release of 
neurotransmitters. Lowering of pH results in increased release of dopamine (Cannizzaro et al., 
2003; Pittaluga et al., 2005), noradrenaline and serotonine from rat brain synaptosomes 
(Pittaluga et al., 2005). Although no direct evidence links pH changes to excitatory amino acid 
efflux, it is thinkable that maintenance of pH homeostasis by CAIs in reducing excitatory amino 
acids outflow from neurons, might protect from ensuing excitotoxicity. 
Previous results obtained in our laboratory, (unpublished results) have shown that the carbonic 
anhydrase inhibitors acetazolamide and AN11-740 tested in an in vitro model of ischemia 
induced by OGD (oxygen and glucose deprivation, OGD) in the CA1 area of rat hippocampus, 
delay significantly the onset of anoxic depolarization (AD), a phenomenon closely related to 
cell damage and death (Pugliese et al., 2006). The evidence that NMDA receptors are essential 
to AD initiation and propagation (Somjen, 2001), supports the possibility that carbonic 
anhydrase inhibitors delays AD by removing the OGD-induced potentiation of glutamate 
transmission, thus reducing the participation of glutamate in triggering the AD. This result 
obtained in an in vitro model of acute OGD-induced depolarization is in favor that carbonic 
anhydrase inhibitors protect in vivo from the functional and tissue damage because of a direct 
central effect that reduces excitotoxicity and precocious brain depolarization induced by the 
lack of O2 and glucose. 
We also must consider that CAIs acetazolamide and AN11-740 in view of their diuretic effect, 
could also reduce brain edema and therefore can mitigate the brain damages induced by cerebral 
ischemia. The presence of edema is a key aggravating factor in ischemic stroke, brain volume 
is limited by the rigidity of the skull, so that even little volume increase lead to high intracranial 
pressure and compression of neural tissue and vasculature (Klatzo, 1985). Rodent brains that 
have undergone middle cerebral artery occlusion (MCAo) develop brain edema and therefore 
swelling during the acute and subacute phases of ischemic injury (Katzman et al., 1977). Guo 
et al. (Guo et al., 2012) demonstrated that after intracerebral hemorrhage in the rat, 
acetazolamide reduced brain edema, neuronal death and neurological deficits. Currently, CAIs 
are used to reduce body fluid volume and edema in pathologies such as glaucoma (Masini et 
al., 2013; Scozzafava et al., 2014). 
Interestingly, 24 hours after pMCAo, a pro-inflammatory cytokine such as TNF-α is increased 
while levels of IL-10, a regulatory cytokine with an anti-inflammatory action, was reduced in 
the plasma of vehicle-treated rats as compared to sham-operated rats. Results are in agreement 
with previous results that have reported an increase of TNF- α in the peripheral plasma 6 and 
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24 hours after pMCAo in mice (Clausen et al., 2017) and 7 days after tMCAo in the rat (Dettori 
et al., 2018). Significant increases of TNF-α serum levels were also found in patients with acute 
stroke, reaching the peak values on day 7 (Intiso et al., 2004) in comparison with controls.  
Modifications of inflammatory markers in the blood likely reflect cytokines that are produced 
in the brain and that reach the systemic circulation. On their turn peripheral inflammatory 
cytokines might contribute to control damage after stroke. Precise cellular-molecular 
mechanisms underlying are unclear, but likely reflect a vicious circle responsible of endothelial 
cell and BBB permeability changes bringing to blood cell infiltration and further brain damage 
(what is called the secondary damage after stroke). Thus, a TNF-α increase and an IL-10 
decrease represent valuable markers over time of the brain damage following an ischemic insult  
(Jickling et al., 2011) Treatment with acetazolamide and AN11-740 did neither modify TNF-α 
or IL-10 levels in the plasma. Likely 24 hours after stroke is a too early time after damage to 
appreciate a protective effect of the CAIs from such damage markers. 
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